NZ284069A - Benzene alkanoic acid substituted pyridine derivatives; medicaments - Google Patents

Benzene alkanoic acid substituted pyridine derivatives; medicaments

Info

Publication number
NZ284069A
NZ284069A NZ284069A NZ28406995A NZ284069A NZ 284069 A NZ284069 A NZ 284069A NZ 284069 A NZ284069 A NZ 284069A NZ 28406995 A NZ28406995 A NZ 28406995A NZ 284069 A NZ284069 A NZ 284069A
Authority
NZ
New Zealand
Prior art keywords
oxy
compound
hexyl
pyridinyl
formula
Prior art date
Application number
NZ284069A
Inventor
Noal Cohen
Ferdinand Kwo-Chen Lee
Keith Alan Yagaloff
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NZ284069A publication Critical patent/NZ284069A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Description

New Zealand Paient Spedficaiion for Paient Number £84069 New Zealand No. 284069 International No.
TO BE ENTERED AFTER ACCEPTANCE AND PUBLICATION Priority dates: 13.04.1994;06.03.1995; Complete Specification Filed: 06.04.1995 Classification:^) C07D213/64; C07D409/04; A61K31/44 Publication date: 24 October 1997 Journal No.: 1421 NEW ZEALAND PATENTS ACT 1953 COMPLETE SPECIFICATION Title of Invention: Substituted pyridine leukotriene B4 antagonists NO DRAWINGS Name, address and nationality of applicant(s) as in international application form: F HOFFMANN-LA ROCHE AG, a Swiss company of 124 Grenzacherstrasse, CH-4002 Basle, Switzerland i# •) New Zealand No. International No. 284069 NEW ZEALAND PATENTS ACT 1953 complete specification Title of Invention: Substituted pyridine leukotriene B4 antagonists Name, address and nationality of applicant(s) as in international application form: F HOFFMANN-LA ROCHE AG, a Swiss company of 124 Grenzacherstrasse, CH-4002 Basle, Switzerland >WO 95/28386 284069 Substituted pyridine leukotriene antagonists The invention relates to compounds of the formula wherein X is O or C=0; Y is CN, S(0)uR8, NR5S02R8, OR9 RlO or -C6H4R10; Z is -(0)y-(CR5R6)s.RlO> -(0)y-(CR5R6)v_OR9 or R*0; Rl, R^ are, independently, aryl, substituted aryl, heteroaryl, lower alkyl or aralkyl; R^ is hydrogen, lower alkyl, halogen or lower alkoxy; R^ is hydrogen or lower alkyl; R5, r6 are, independently, each occurrence, hydrogen or lower alkyl; R? is hydroxy, lower alkoxy or NR5R6; R8 is lower alkyl, aryl, substituted aryl or aralkyl; R9 is hydrogen, lower alkyl, aryl, substituted aryl, aralkyl, lower alkanoyl or aroyl; RlO is COR7, CONHSO2R8 or lH-tetrazol-5-yl; m is an integer from 3 to 8; n and s are, independently, an integer from 1 to 12; t is an integer from 0 to 1; u is an integer from 0 to 2; v is an integer from 2 to 12; z Pop/So 29.3.95 wo 95/28386 pct/ep95/01262 y is an integer from 0 to 1; and z is an integer from 0 to 1; with the proviso that either Y is RlO or -C6H4RIO or Z is -(O)y-(CR5r6)s_r10 orRlO and the further proviso that when n=l, Y is RlO or -C6H4RI0, an optical isomer when R^ and R6 are not both hydrogen or the same lower alkyl and, when R? is hydroxy, a pharmaceutically acceptable salt thereof with a base.
The compounds of formula I are potent leukotriene B4 antagonists and are therefore useful in the treatment of inflammatory diseases such as psoriasis, rhinitis, chronic obstructive pulmonary disease, inflammatory bowel disease, asthma, acute respiratory distress syndrome, cystic fibrosis, allergy, arthritis such as rheumatoid arthritis, dermatitis such as contact dermatitis, NSAID-induced gastropathy, gout, ischemia/ reperfusion injury, and trauma-induced inflammation, such as, spinal cord injury.
In another aspect, the invention relates to pharmaceutical compositions and methods of use comprising the compound of formula I.
As used herein, the term "aryl" preferably denotes naphthalenyl, phenyl, anthracenyl, phenanthrenyl or the like. The term "substituted aryl" preferably denotes an aryl group which may be mono-, di- or trisubstituted by, for example, halogen, trifluoromethyl, lower alkyl, phenyl, lower alkoxy, cyano or nitro or combinations thereof.
The term "heteroaryl" denotes a 5- or 6- membered aromatic heterocyclic radical containing one or more hetero atoms, selected from nitrogen, oxygen and sulfur, which radical may optionally be substituted by one or two lower alkyl, lower alkoxy groups, chlorines or fluorines. It is understood that heterocyclic refers to a carbocyclic moiety in which one or more of the carbons are replaced, independently, by oxygen, nitrogen or sulfur.
Exemplary of 5- or 6- membered aromatic heterocyclic radicals are pyridinyl, imidazolinyl, thienyl, 2-chlorothienyl, furyl, pyrimidinyl, oxazolinyl or the like.
The term "lower alkyl", denotes a straight or branched chain saturated hydrocarbon containing 1 to 7 carbon atoms, preferably from 1 to 4 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, butyl, t-butyl, neopentyl, pentyl, heptyl, and the like.
The term "aralkyl" denotes an alkyl group substituted by an aryl group, for example, benzyl, phenethyl, or the like, which may be substituted by halogen, trifluoromethyl, lower alkyl, lower alkoxy, cyano, nitro or the like.
The term "halogen" denotes all the halogens, i.e., bromine, chlorine, fluorine, and iodine.
The term "lower alkoxy" denotes an , alkyl ether group in which the alkyl group is as described above, for example, methoxy, ethoxy, propoxy, pentoxy and the like.
The term "lower alkanoyl" denotes a primary or secondary alkanoyl group containing up to 7 carbon atoms such as acetyl, propionyl, butyryl, isobutyryl and the like.
The term "aroyl" preferably denotes the benzoyl group or a substituted benzoyl group, for example a nitrobenzoyl group such as p-nitrobenzoyl or a halobenzoyl group such as o-, m- or p-iodobenzoyl.
The group -C6H4R *0 may be ortho, meta or para substituted.
Exemplary of the group -(CR5R6)-n>s v are 1,1-dimethyl-propylenyl, 2,2-dimethylpropylenyl, 2,6-dimethylheptylenyl, 1-methyl-l-ethylpentylenyl, l-ethyl-3-methylhexylenyl or the like.
As used herein, a leaving group denotes halogen, preferably, bromine and iodine; lower alkylsulfonyloxy, such as, (methylsulfonyl)oxy, (trifluoromethylsulfonyl)oxy or the like; arylsulfonyloxy, such as, para-toluenesulfonyloxy or the like.
As used herein, an acid sensitive hydroxyl protecting group denotes any protecting group for hydroxyl which can be cleaved by acid treatment, such as tetrahydropyranyl, trityl, 1-ethoxyethyl and the like.
A preferred group of compounds of formula I is one in which Rl and R^ are aryl and R^ and R4 are hydrogen.
A further preferred group of compounds of formula I is one in which Rl and R3 are aryl, R^ and R^ are hydrogen, Y is S(0)uR8, OR9 or RlO and Z is -(0)y(CR5R6)s_RlO or -(O)y-(CR5R6)v-OR9.
A more preferred group of compounds of formula I is one in which Rl and R^ are aryl, R^ and R^ are hydrogen, Y is RlO, Z is -(0)y-(CR5R6)v-OR9 or -(0)y-(CR5R6)s-RlO, 0r R? is hydroxy, R^ is hydrogen, and RlO is -COR^.
A most preferred group of compounds of formula I is one in which Rl and R^ are aryl, R^ and R^ are hydrogen, X is 0, z is zero, t is 1, n is 3-5, Y is RlO, Z is -(0)y-(CR5R6)v_OR9 or -(0)y- (CR5R6)s-RlOt y is zero^ s or v is 2-6, R? is hydroxy, R^ is hydrogen, and R*0 is -COR?.
Another more preferred group of compounds of formula I is one in which R* and R^ are aryl, R^ and R^ are hydrogen, Y is S(0)uR8 or OR9, Z is -(0)y-(CR5R6)s-R10, r7 is hydroxy, R8 is lower alkyl, R^ is hydrogen and R*0 is -COR?.
Another most preferred group of compounds of formula I is one in which R* and R^ are aryl, R^ and R^ are hydrogen, X is O, z is zero, t is 1, n is 3-5, Y is S(0)uR8 or OR^, Z is -(O)y-(CR5R6)s.RlOt y is zero, s is 2-6, R? is hydroxy, R8 is lower alkyl, R^ is hydrogen and R*0 is -COR?.
Most preferred examples of this invention are: 2-(3-Carboxypropoxy)-6-[6-[(4,6-diphenyl-2-pyridinyl)-oxy]hexyl]benzenepropanoic acid 2-[6-[(4,6-Diphenyl-2-pyridinyl)oxy]hexyl]-6-[(4-hydroxy-4-methylpentyl)oxy]benzenepropanoic acid 2-[6-[(4,6-Diphenyl-2-pyridinyl)oxy]hexyl]-6-[4-(methyl-sulfonyl)butoxy]benzenepropanoic acid 4-[3-[6-[(4,6-Diphenyl-2-pyridinyl)oxy]hexyl]-2-(3-hydroxy-3-methylbutyl)phenoxy]butanoic acid 3-(2-Carboxyethyl)-4-[6-[(4,6-diphenyl-2-pyridinyl)-oxy]hexyl]-benzenepentanoic acid -(3-Carboxypropoxy)-2-[6-[(4,6-diphenyl-2-pyridinyl)-oxy]hexyl]benzenepropanoic acid.
Other preferred examples include: 2-[3-(2-Carboxyphenyl)propoxy]-6-[6-[(4,6-diphenyl-2-pyridinyl)oxy]hexyl]benzenepropanoic acid 2-[3-(3-Carboxyphenyl)propoxy]-6-[6-[(4,6-diphenyl-2-pyridinyl)oxy]hexyl]benzenepropanoic acid 284 2-(3-Carboxypropoxy)-6-[5-[(4,6-diphenyl-2-pyridinyl)-oxy]pentyloxy]benzenepropanoic acid 2-(3-Carboxypropoxy)-6-[6-[(4-phenyl-6-(4-fluoro-phenyl)-2-pyridinyl)oxy]hexyl]benzenepropanoic acid 2-(3-Carboxypropoxy)-6-[6-[(4-phenyl-6-(2-thienyl)-2-pyridinyl)oxy]hexyl]benzenepropanoic acid 2-[(4-Carboxyphenyl)methoxy]-6-[6-[(4,6-diphenyl-2-pyridinyl)oxy]hexyl]benzenepropanoic acid 2-[(2-Carboxyphenyl)methoxy]-6-[6-[(4,6-diphenyl-2-pyridinyl)oxy]hexyl]benzenepropanoic acid 2-[(3-Carboxyphenyl)methoxy]-6-[6-[(4,6-diphenyl-2-pyridinyl)oxy]hexyl]benzenepropanoic acid.
Compounds of general formula I as well as their pharmaceutical^ acceptable salts can be manufactured in accordance with the invention by a) reacting a compound of the general formula MCHzWtO), Z wherein L is a leaving group, Rl, R2, R3, R4, R5, R6, X, m, n, z and t are as previously defined and Y' and Z' are Y and Z as 1-1 H with a compound of the general formula (X)t(CR5R6)nY* 1-2 N.Z. PATENT OFF; S~? 1S37 WO 95/28386 PCT/EP95/01262 previously defined with the proviso that in any COR7 lower alkoxy, or PJ 0 b) saponifying a compound of the general formula 1, wherein Y and/or Z contain(s) a -COR7 group and R7 is lower alkyl to mono- or di-acid derivatives, or c) reacting a compound of the general formula I, wherein the group(s) Y and/or Z contain(s) the group -COOH, with an amine of the formula HNRSR13 wherein R5 is as defined above and R13 is hydrogen, lower alkyl or a group -SO2R8 and R8 is as previously described, to the corresponding mono- or disubstituted amides or sulfonamides, or d) reacting a compound of the general formula I, wherein Y is -CN with an metal azide to a compound of the formula I, wherein Y is lH-tetrazol-5-yl, and e) if desired, converting a compound of the general formula I into a pharmaceutically acceptable salt.
Further, the compounds of formula I can be prepared as hereinafter described in Reaction Schemes 1-5 in more detail. 1 0 ftp? wo 95/28386 Reaction Scheme 1 pct/ep95/01262 R3 (xmcr'R^Y- i H 1-1 1-2 Base R1 N O—(CH2)m-(0): la MOH JZf TOtCCR^Y' O— lb JQ OO.CCR^^Y" Z" wherein L is a leaving group, M is an alkali metal cation, Rl. r2, r3, r4, r5, r6, x, m, n, z, and t are as previously defined. Y' is Y as previously defined with the proviso that any COR? are COR?' wherein R?' is lower alkoxy. Y" is Y as previously defined with the provisos that any COR? are COR?" wherein R?" is hydroxy, and any R9 are R9" wherein R9 is hydrogen. Z' is Z as previously defined with the proviso that any COR? are COR?' wherein R?' is lower alkoxy. Z" is Z as previously defined with the provisos that any COR? are COR?" wherein R?" is hydroxy, and any R^ are r9" wherein R^" is hydrogen.
In Reaction Scheme I, the pyridone of formula 1-1 is alkylated with a compound of formula 1-2 giving the product of formula la. This alkylation is carried out in the presence of a base, and in an inert solvent. Among the preferred bases utilized in this alkylation reaction are alkali metal carbonates such as sodium or potassium carbonate, or transition metal carbonates such as silver carbonate. Preferred inert solvents for carrying out this alkylation are toluene and N,N-dimethyl-formamide. It is preferred that this alkylation be carried out within a temperature range of from 80 to 120°C. The compound of formula la can be recovered by conventional chromatography. Saponification of the compound of formula la, which can contain one or two ester functions, is carried out under standard conditions for the saponification of esters, giving the corresponding mono- or diacid of formula lb. For example, this saponification can be carried out using an alkali metal hydroxide, such as sodium, potassium, or lithium hydroxide, in a lower alkanol solvent such as methanol or ethanol, within a temperature range of from 60 to 80 °C. The acid of formula lb is recovered by recrystallization.
Exemplary of known intermediates of formula 1-1 are the following which are prepared as described in Journal of Medicinal Chemistry, Vol. 35, pp. 4315-4324, 1992: 4,6-Diphenyl-2-pyridone, 4-(3-Methoxyphenyl)-6-phenyl-2-pyridone, 4-(2-Fluorophenyl)-6-phenyl-2-pyridone, 6-(4-Fluorophenyl)-4-phenyl-2-pyridone, and 6-(4-Methylphenyl)-4-phenyl-2-pyridone.
Other examples of known intermediates of formula 1-1 are: 4,6-Diphenyl-5-methyl-2-pyridone, prepared as described in Tetrahedron Letters, Volume 29, pp. 4855-4858, 1988, 6-tert.-Butyl-4-phenyl-2-pyridone and 4-Phenyl-6-(2-thienyl)-2-pyridone both prepared as described in International Patent Application WO 92/01675, 4,6-Diphenyl-5-methoxy-2-pyridone prepared as described in J. Chem. Soc., pp. 2588-2594, 1959, and -Bromo-4,6-diphenyl-2-pyridone prepared as described in An. Quim., Vol. 75, pp. 124-127, 1979.
Exemplary of known intermediates of formula 1-2 are the following which are prepared as described in U.S. Patent No. 5,273,999: 2-[[5-[(Methylsulfonyl)oxy]pentyl]oxy]-5-(4-ethoxy-4-oxobutoxy)benzenepropanoic acid ethyl ester 2-[6-[(Methylsulfonyl)oxy]hexyl]-5-(4-methoxy-4-oxobutoxy)-benzenepropanoic acid methyl ester 6-(5-Ethoxy-5-oxopentyloxy)-2-[[5-[(methylsulfonyl)oxy]-pentyl]oxy]benzenepropanoic acid methyl ester 4-[(5-Bromopentyl)oxy]-3-(3-ethoxy-3-oxopropyl)-5-oxobenzenepentanoic acid ethyl ester 4-[(5-Bromopentyl)oxy]-3-(3-ethoxy-3-oxopropyl)-y-oxobenzene-butanoic acid ethyl ester (£L)-4-[3-(3-Methoxy-3-oxo-l-propenyl)-4-[6-[(methyl-sulfonyl)oxy]hexyl]phenoxy]butanoic acid methyl ester 2-(5-Methoxy-5-oxopentyloxy)-6-[6-[(methylsulfonyl)-oxy]hexyl]benzenepropanoic acid methyl ester 2-[[5-[(Methylsulfonyl)oxy]pentyl]oxy]-4-(4-methoxy-4-oxobutoxy)benzenepropanoic acid methyl ester 2-(2-Methoxy-2-oxoethoxy)-6-[6-[(methylsulfonyl)-oxy]hexyl]-benzenepropanoic acid methyl ester 2-[(6-Methoxy-6-oxohexyl)oxy]-6-[6-[(methylsulfonyl)-oxy]hexyl]benzenepropanoic acid methyl ester 4-[[5-[(Methylsulfonyl)oxy]pentyl]oxy]-l,3-benzene-dipropanoic acid dimethyl ester 2-(3-Methoxy-3-oxopropyl)-3-[6-[(methylsulfonyl)-oxy]hexyl]benzenehexanoic acid methyl ester 2-[(4,4-Dimethyl-5-methoxy-5-oxopentyl)oxy]-6-[6-[(methyl-sulfonyl)oxy]hexyl]benzenepropanoic acid methyl ester 2-[[5-(Acetyloxy)pentyl]oxy]-6-[6-[(methylsulfonyl)oxy]-hexyl]benzenepropanoic acid methyl ester 2-[(8-Methoxy-8-oxooctyl)oxy]-6-[6-[(methylsulfonyl)-oxy]hexyl]benzenepropanoic acid methyl ester 2-[(9-Methoxy-9-oxononyl)oxy]-6-[6-[(methylsulfonyl)-oxy]hexyl]benzenepropanoic acid methyl ester 2-(4-Methoxy-4-oxobutoxy)-6-[6-[(methylsulfonyl)oxy]-hexyljbenzenepropanoic acid methyl ester 4-(6-Bromohexyl)-3-(3-ethoxy-3-oxopropyl)-S-oxobenzenepentanoic acid ethyl ester 4-(5-Bromopentyloxy)-3-(3-ethoxy-3-oxopropyl)benzene-pentanoic acid ethyl ester 4-(6-Bromohexyl)-3-(3-ethoxy-3-oxopropyl)benzene-pentanoic acid ethyl ester 2-[(7-Methoxy-7-oxoheptyl)oxy]-6-[6-[(methylsulfonyl)-oxy]hexyl]benzenepropanoic acid methyl ester.
Reaction Scheme 2 OH yCt • - Ri'OtCHj),-^ ^COR^ 2-1 2-2 O— (CHj), Catalyst f^A ^.OH H2. i R5R« V^COR'' RnO(CH2)a corT * 2-3 0-(CHjW 0-(CHjV2 jPj R^R* **" i R"°(CH^V-CORr HOccn^X^.^ 2-4 2-5 V0"'01^ 0H /l Rs R® j(Pj R^R6 «C„^\^C0Rr 2-6 wherein, R^, r6, and L are as previously defined, R?' is lower alkoxy, RH is an acid sensitive hydroxyl protecting group, and q and r are, independently, an integer from 1-10.
In Reaction Scheme 2, a phenol of formula 2-1, which represents known compounds prepared as described in U.S. Patent No. 5,273,999, is alkylated with a compound of formula 2-2, which represents known compounds or compounds which can be prepared by known methods, in the presence of a base, to give a product of formula 2-3 which is recovered by standard chromatographic methods. This alkylation reaction is preferably carried out using an alkali metal carbonate such as sodium or potassium carbonate as the base, within a temperature range of from about 25 °C. to about 110°C., in a polar, aprotic solvent such as acetonitrile, N,N-dimethyl-formamide, 2-butanone, or dimethyl sulfoxide. Catalytic hydro-genation of the compound of formula 2-3 gives the product of formula 2-4 which is recovered by chromatography. It is preferred that this hydrogenation be carried out using palladium on carbon as the catalyst, and ethyl acetate as the solvent. The compound of formula 2-4 is converted to the compound of formula 2-5 using conditions generally employed for the removal of acid sensitive hydroxyl protecting groups. For example, the compound of formula 2-4 can be treated with an acid in a lower alkanol solvent. It is preferred that this deprotection reaction be carried out using oxalic acid in aqueous methanol, within a temperature range of from about 25°C to about 65 °C. The product of formula 2-5 is recovered by chromatography and is converted to the corresponding derivative 2-6 using standard methods known in the art for transforming hydroxy groups into leaving groups. These methods include treatment with halogenating reagents such as N-bromosuccinimide/triphenylphosphine or iodine/triphenyl-phosphine in dichloromethane. Alternatively, the compound of formula 2-5 can be converted to the corresponding sulfonate of formula 2-6 by conventional methods such as treatment with an arylsulfonyl chloride and an organic amine. These sulfonic esters can, in turn, be converted into the corresponding iodides of formula 2-6 by treatment with an alkali metal iodide in a polar, aprotic solvent. It is preferred that this conversion be carried out using sodium iodide, in acetonitrile, within a temperature range of 20-80 °C. The compounds of formula 2-6 are recovered by conventional extractive work-up.
Reaction Scheme 3 OH 2-1 + uayjr cxch^V way.r Acid R<<0<CHJ,' wherein L, R7', R11, Y\ n, and q are as previously defined.
In Reaction Scheme 3, a phenol of formula 2-1 is alkylated with a compound of formula 3-1, which represents known compounds or compounds which can be prepared by known methods, in the presence of a base, to give a product of formula 3-2 which is recovered by standard chromatographic methods. This alkylation reaction is carried out as described in Reaction Scheme 2 for the conversion of the compound of formula 2-1 to the compound of formula 2-3. Catalytic hydrogenation of the compound of formula 3-2 is carried out as described in Reaction Scheme 2 for the conversion of the compound of formula 2-3 to the compound of formula 2-4. The deprotection of the compound of formula 3-3 to give the alcohol product of formula 3-4 is carried out as described in Reaction Scheme 2 for the conversion of the compound of formula 2-4 to the compound of formula 2-5. The compound of formula 3-4 is transformed into the compound of formula 3-5 as described in Reaction Scheme 2 for the conversion of the compound of formula 2-5 to the compound of formula 2-6.
Reaction Scheme 4 R OfCHj^i OH ^ COR 2.1 rd Add 4-1 X6 HOtCHaVr V^mR7, 4-2 4-3 HCKCHjJ^i L(CHJwCORT 45 R* R* CKCHj^COR7 •°L HOW^ X OH ^ «KV 0(CHa).C0Rr LtCHjV,' •oL 4-7 r V wheicin R5* is lower alkyl, M' is lithium or halomagnesium, and L, R?', R^, n, and q are as previously defined.
In Reaction Scheme 4, a phenol of formula 2-1 is catalytically hydrogenated to give the corresponding reduced compound of formula 4-1 as described in Reaction Scheme 2 for the conversion of the compound of formula 2-3 to the compound of formula 2-4. The deprotection of the compound of formula 4-1 to give the alcohol product of formula 4-2 is carried out as described in Reaction Scheme 2 for the conversion of the compound of formula 2-4 to the compound of formula 2-5. Reaction of the compound of formula 4-2 with an excess of the organometallic reagent of formula 4-3, which represents known compounds, gives the triol of formula 4-4. It is preferred that the reagent 4-3 be a Grignard or organolithium reagent and that this reaction be carried out in an inert solvent such as ether or tetrahydrofuran, within a temperature range of from 0°C to about 65 °C. The product of formula 4-4 is recovered by chromatography. Alkylation of the compound of formula 4-4 with a compound of formula 4-5, which represents known compounds, is carried out as described in Reaction Scheme 2 for the conversion of the compound of formula 2-1 to the compound of formula 2-3, and gives the compound of formula 4-6, which is recovered by chromatography. The compound of formula 4-6 is transformed into the compound of formula 4-7 as described in Reaction Scheme 2 for the conversion of the compound of formula 2-5 to the compound of formula 2-6.
Reaction Scheme 5 VV fh o— rrn,i_ - (X),(CR5R6)nY" hnr5r13 J R1' "NT ^O-CCHa^-COr Z" lb k M"(N3)k N=N (X^CR^s—( I N-N MOH Rl' "N' " 0- (CH2)m " (Of^V "A- RlxkN^k Q_ (CHa)m. (o)r^\_ H Z" If wherein M, R1, R2, R3, R4, R5, R6, X, Y", Z, Z'\ m, n, z, and t are as previously defined and Y'" is Y as previously defined with the proviso that any COR? is COR? " wherein R?"' is NR5r6s z"' is Z as previously defined with the proviso that any COR? is COR? " wherein R?"' is NR5r6, Rl3 is hydrogen, lower alkyl, or S02R^ wherein R** is as previously defined, M" is sodium, lithium, aluminum, magnesium, or tri(lower alkyl)stannyl, and k is an integer from 1 to 3 depending on the valence of M".
In Reaction Scheme 5, an acid of formula lb (Reaction Scheme 1) is converted to the corresponding amide or acylsulfonamide of formula Ic by reaction with the amine or sulfonamide r5r13nh, which represents known compounds.
This reaction can be carried out using any of the standard methods of forming amides or acylsulfonamides from acids. These include treatment of the acid with l.l'-carbonyldiimida-zole and the amine or exposure of the acid to a base, a carbodiimide and the amine or sulfonamide. It is understood that if more than one carboxyl moiety is present in the starting acid, all such groups will be converted to the corresponding amide or acylsulfonamide linkage. It is preferred that the reaction be performed by treating the acid of formula lb with l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 1-hydroxybenzotriazole, 4-dimethylaminopyridine, and the amine or sulfonamide R5Rl3NHt in dichloromethane solution, at ambient temperature. The amide or acylsulfonamide of formula Ic is recovered by chromatography or recrystallization.
Treatment of the nitrile of formula Id, which can be prepared as described in Reaction Schemes 1 and 3, with a metal azide M"(N3)k, which represents known compounds, gives the tetrazole of formula Ie, which is recovered by chromatography or recrystallization. This reaction can be carried out using any of the common azide reagents including sodium azide, lithium azide, magnesium azide, aluminum azide, and tri(lower alkyl)stannyl azides. It is preferred that this reaction be carried out using tri(n-butyl)stannyl azide in dioxane solution, within a temperature range of from about 80°C to about 100°C. Saponification of the ester Ie is carried out as described in Reaction Scheme 1 for the conversion of the compound of formula la to the compound of formula lb, giving the tetrazole acid of formula If which is recovered by chromatography or recrystallization.
Reaction Scheme 6 PH L-(CH2)n X$ . x?-«* RnO(CH2)q+2 COR7 4-1 6-1 RnO(CH2)q+2' HCXCH2V2 COR* *** .
COR7 ™"'~0 COR7 L(CH2),+2 "COR7 6-4 wherein L, R7, R11, n, and q arc as previously defined.
In Reaction Scheme 6, a phenol of formula 4-1 is alkylated with a compound of formula 6-1, which represents known compounds or compounds which can be prepared by known methods, in the presence of a base, to give a product of formula 6-2 which is recovered by standard chromatographic methods. This alkylation reaction is carried out as described in Reaction Scheme 2 for the conversion of the compound of formula 2-1 to the compound of formula 2-3. Deprotection of the compound of formula 6-2 to give the alcohol product of formula 6-3 is carried out as described in Reaction Scheme 2 for the conversion of the compound of formula 2-4 to the compound of formula 2-5. The compound of formula 6-3 is transformed into the compound of formula 6-4 as described in Reaction Scheme 2 for the conversion of the compound of formula 2-5 to the compound of formula 2-6. - 21 -Reaction Scheme 7 /» HO-(CH2)v t'd • ~ Rt02CN»NC02Rt 7-1 0-(CH2)y RnO(CH2)q'^^ ^^COR7 7-2 H2, catalyst COR7 O- (CHzX ^ Acid —A.
COR COR7" 7-3 p—(CH2)V vx cort HO(CH2)q+2^^\^^ 'COR7 7-4 O- (CH2)v jC$ ^3-a*T UCH2)q+2'^^\ V^COR7" 7-5 wherein L, Rr, R11, q, and v are as previously defined, and Ar is aryl.
In Reaction Scheme 7, a phenol of formula 2-1 is condensed with a compound of formula 7-1, which represents known compounds or compounds which can be prepared by known methods, in the presence of a phosphine and an azodicarboxylic diester, to give a product of formula 7-2 which is recovered by standard chromatographic methods. Among the preferred phosphines which can be employed in this condensation are triaryl phosphines such as triphenylphosphine. Among the preferred azodicarboxylic diesters which can be employed in this condensation are lower alkyl azodicarboxylic diesters such as diethyl azodicarboxylate. It is preferred that this condensation be carried out in an inert, ether solvent such as diethyl ether or tetrahydrofuran within a temperature range of 25-75 °C.
Catalytic hydrogenation of the compound of formula 7-2 to give the corresponding saturated compound 7-3 is carried out as described in Reaction Scheme 2 for the conversion of the compound of formula 2-3 to the compound of formula 2-4. Deprotection of the compound of formula 7-3 to give the alcohol product of formula 7-4 is carried out as described in Reaction Scheme 2 for the conversion of the compound of formula 2-4 to the compound of formula 2-5. The compound of formula 7-4 is transformed into the compound of formula 7-5 as described in Reaction Scheme 2 for the conversion of the compound of formula 2-5 to the compound of formula 2-6.
Keaction Scheme 8 UCHjJ.COR 4-5 r But HO CORr M 0(CHJ)»C0RT MR CKCHjX.COR7' L(CHjXL UCH^O OCCH^COR7 COR «-5 *Xx R'^N-^O I H 1-1 Bue R> ,XX>^ CKCHJXCOR7 COR S-6 wherein R1, R2, R3, R4, R7, L, M, n and v are as previously defined.
In Reaction Scheme 8, alkylation of a coumarin of formula 8-1, which represents compounds known in the art, with an ester of formula 4-5, which also represents compounds known in the art, in the presence of a base, gives the product of formula 8-2. This alkylation is carried out under standard conditions for effecting the alkylation of a phenol such as those described in Reaction Scheme 2 for the conversion of the compound of formula 2-1 to the compound of formula 2-3. The compound of formula 8-2 is recovered by conventional chromatographic methods and is converted to the corresponding 2-hydroxycinnamate of formula 8-3 by alcoholysis of the lactone ring using an alkali metal lower alkoxide in a lower alkanol solvent. This transformation is carried out using lithium, sodium, or potassium lower alkoxide. It is preferred that this transformation be carried out in methanol or ethanol with sodium methoxide or sodium ethoxide, at a temperature in the range of 60-120 °C. The compound of formula 8-3 is recovered by standard chromatographic methods. Alkylation of the compound of formula 8-3 with a compound of formula 8-4, which represents known compounds such as 1,5-dibromopentane, l-bromo-3-chloro-propane and the like, is carried out as described in Reaction Scheme 2 for the conversion of the compound of formula 2-1 to the compound of formula 2-3, and affords the compound of formula 8-5 which is recovered by chromatography. Alkylation of the pyridone of formula 1-1 with the compound of formula 8-5 is carried out as described in Reaction Scheme 1 for the conversion of the compound of formula 1-1 to the compound of formula la, and gives the compound of formula 8-6, which is recovered by chromatography. Catalytic hydrogenation of the compound of formula 8-6 using the procedure described in Reaction Scheme 3 for the conversion of the compound of formula 3-2 to the compound of formula 3-3, gives the corresponding saturated compound of formula 8-7, a sub-species of la.
The invention also relates to a salt of the compound of formula I when it contains an acidic functionality which lends itself to salt formation with a base. Salts of compounds of formula I which have a carboxy group are prepared by the reaction with a base having a non-toxic, pharmacologically acceptable cation. In general, any base which will form a salt with a carboxylic acid and whose pharmacological properties will not cause an adverse physiological effect is within the scope of this invention.
Suitable bases thus include, for example, the alkali metal and alkaline earth metal hydroxides, carbonates or the like, for example, calcium hydroxide, sodium hydroxide, sodium carbonate, potassium carbonate or the like, ammonia, primary, secondary and tertiary amines, such as, monoalkylamines, dialkylamines, trialkylamines, for example, methylamine, diethylamine, triethylamine or the like, nitrogen containing heterocyclic amines, for example, piperidine or the like. A salt thus produced is the functional equivalent of the corresponding compound of formula I wherein R? is hydroxy and one skilled in the art will appreciate that the variety of salts embraced by the invention is limited only by the criterion that a base employed in forming the corresponding salts be both non-toxic and physiologically acceptable.
The useful activity of the compounds of formula I as leukotriene B4 antagonists can be demonstrated as hereinafter set forth.
Guinea Pig Bronchoconstriction In Vivo.
Male guinea pigs (Hartley strain) weighing 300 to 500 g are anesthetized with urethane (2g/kg) intraperitoneally and a polyethylene cannula is inserted into the jugular vein for drug administration. Tracheal pressure is recorded from a cannula inserted into the trachea and connected to a Gould P23ID pressure transducer. After surgical preparation of the animals, a period of time is allowed for pulmonary functions to stabilize. The test compound is administered orally 2 hours prior to leukotriene B4 administration according to the following protocol: Animals are paralyzed with succinylcholine (1.2 mg/kg i.v.) and mechanically respirated (Harvard rodent respirator) at 40 breaths/minute and 2.5 cc tidal volume. Propranolol (0.1 mg/kg) is then administered intravenously five minutes prior to leukotriene B4 administration. Animals are then challenged with an intermediate constrictory dose of leukotriene B4 (200 }ig/kg) delivered intravenously.
The change (cm H2O) between pre and peak ventilatory pressure readings is averaged for six control and six drug treated animals. The percent inhibition is calculated from the formula: ((Control - Drug Treated)/Control)xl00 When compounds of formula I were tested, the percent inhibition of a 0.1 mg/kg oral dose was as follows. % inhibition, 0.1 mg/kg test compound dose 2-(3-Carboxypropoxy)-6-[6-[(4,6-diphenyl- 8 6 2-pyridinyl)oxy]hexyl] benzenepropanoic acid 2-[6-[(4,6-Diphenyl-2-pyridinyl)oxy]hexyl]-6- 2 7 [(4-hydroxy-4-methylpentyl)oxy]benzenepropanoic acid 2-[6-[(4,6-Diphenyl-2-pyridinyl)oxy]hexyl]-6- 5 5 [4-(methy Isulfony l)butoxy ] benzenepropanoic acid 4-[3-[6-[(4,6-Diphenyl-2-pyridinyl)oxy]hexyl]-2- 41 (3-hydroxy-3-methylbutyl)phenoxy]butanoic acid -(3-Carboxypropoxy)-2-[6-[(4,6-diphenyl-2- 40 pyridinyl)oxy]hexyl]benzenepropanoic acid 2-[3-(2-Carboxyphenyl)propoxy]-6-[6-[(4,6- 5 6 diphenyl-2-pyridinyl)oxy]hexyl]benzenepropanoic acid 2-[3-(3-Carboxyphenyl)propoxy]-6-[6-[(4,6- 5 0 diphenyl-2-pyridinyl)oxy]hexyl] benzenepropanoic acid 2-(3-Carboxypropoxy)-6-[[5-[(4,6-diphenyl-2- 6 2 pyridinyl)oxy]pentyl]oxy]benzenepropanoic acid 2-(3-Carboxypropoxy)-6-[6-[[6-(4-fluorophenyl)- 6 8 4-phenyl-2-pyridinyl]oxy]hexyl]benzenepropanoic acid 2-(3-Carboxypropoxy)-6-[6-[[4-phenyl-6- 6 5 (2-thienyl)-2-pyridinyl]oxy]hexyl]benzene-propanoic acid 2-[(4-Carboxyphenyl)methoxy]-6-[6-[(4,6- 4 2 diphenyl-2-pyridinyl)oxy]hexyl] benzenepropanoic acid 2-[(2-Carboxyphenyl)methoxy]-6-[6-[(4,6- 5 5 diphenyl-2-pyridinyl)oxy]hexyl]benzene-propanoic Acid 2-((3-Carboxyphenyl)methoxy]-6-[6-[(4,6- 42 diphenyl-2-pyridinyl)oxy]hexyl] benzenepropanoic Acid Isolation of Intact Neutrophils Human neutrophils are prepared from citrated or heparinized blood. The blood was diluted 1:1 with Hank's balanced salt solution (HBSS) minus calcium and magnesium and underlayed with 10 ml lymphocyte separation medium (Organon Teknika), followed by centrifugation at 500 x g for 30 minutes, at room temperature. Supernatants are removed down to the red blood cell pellet. HBSS minus calcium and magnesium is added to give 25 ml. To this is added 25 ml 6% dextran in 0.85% NaCl. Samples are mixed and allowed to stand 20 minutes at room temperature. Supernatants are removed and centrifuged at 500 x g for 5 minutes at 4°C. Pellets arc resuspended with 20 ml 0.2% saline for 20 seconds followed by the addition of 20 ml 1.6% saline. Samples are centrifuged at 500 x g for 5 minutes at 4°C. The lysis is repeated and the cells (90-95% neutrophils) are resuspended at 2x10^ cell/ml in GEY's salt solution.
LTBa Receptor Binding Assay Binding assays are performed in microtiter wells. Isolated human neutrophils in Gey's salt solution are incubated on ice for 45 minutes with 0.5nM 3H-LTB4 in the presence or absence of test compounds. Assays are terminated by adding 12 ml ice cold 50 mM Tris (pH 7.4) followed by rapid nitration under vacuum through GF/C filters. Radioactivity is determined by scintillation counting. Non- specific binding is defined as the binding not displaced by 100 fold excess of unlabelled LTB4. Specific binding is defined as the difference between total binding and non-specific binding. Non linear analysis of the binding data is performed using LIGAND (Munson and Rodbard, 1980). Ki (Inhibition Constant) values were determined using the Cheng-Prusoff relationship (Cheng and Prusoff, 1973).
When representative compounds of formula I of the invention were tested, the results, as set forth below, expressed as inhibition of 3H-LTB4 binding, were obtained.
HUMAN NEUTROPHIL TEST COMPOUND CELLS (Ki nM) 2-(3-Carboxypropoxy)-6-[6-[(4,6-diphenyl-2- 1 pyridinyl)oxy]hexyl]benzenepropanoic acid 2-[6-[(4,6-Diphenyl-2-pyridinyl)oxy]hexyl]-6- 40 [(4-hydroxy-4-methylpentyl)oxy] benzenepropanoic acid 2-[6-[(4,6-Diphenyl-2-pyridinyl)oxy]hexyl]-6- 45 [4-(methylsulfonyl)butoxy]benzenepropanoic acid 4-[3-[6-[(4,6-Diphenyl-2-pyridinyl)oxy]hexyl]-2- 25 (3-hydroxy-3-methylbutyl)phenoxy]butanoic acid -(3-Carboxypropoxy)-2-[6-[(4,6-diphenyl-2- 1 pyridinyl)oxy]hexyl]benzenepropanoic acid 2-[3-(2-Carboxyphenyl)propoxy]-6-[6-[(4,6- 1 diphenyl-2-pyridinyl)oxy]hexyl] benzenepropanoic acid 2-(3-Carboxypropoxy)-6-[[5-[(4,6-diphenyl-2- 0.4 pyridinyl)oxy]pentyl]oxy] benzenepropanoic acid 2-(3-Carboxypropoxy)-6-[6-[[6-(4-fluorophenyl)- 0.2 4-phenyl-2-pyridinyl]oxy]hexyl]benzenepropanoic acid 2-(3-Carboxypropoxy)-6-[6-[[4-phenyl-6- 0.6 (2-thienyl)-2-pyridinyl]oxy]hexyl]benzene-propanoic acid 2-[(4-Carboxyphenyl)methoxy]-6-[6-[(4,6- 0.3 diphenyl-2-pyridinyl)oxy]hexyl]benzene- propanoic acid 2-[(2-Carboxyphenyl)methoxy]-6-[6-[(4,6- 0.2 diphenyl-2-pyridinyl)oxy]hexyl]benzene- propanoic acid 2-[(3-Carboxyphenyl)methoxy]-6-[6-[(4,6- 0.3 diphenyl-2-pyridinyl)oxy]hexyl]benzene-propanoic acid In the practice of the invention, the dose of a compound of formula I or a salt thereof to be administered and the frequency of administration will be dependent on the potency and duration of activity of the particular compound of formula I or wo 95/28386 pct/ep95/01262 salt to be administered and on the route of administration, as well as the severity and nature of the condition and age of the mammal to be treated and the like. Oral doses of a compound of formula I or a salt thereof contemplated for use in practicing the invention can be in the range of from 2 mg to about 2 g per day, preferably about 2 mg to about 1 gm per day, either as a single dose or in divided doses.
A compound of formula I, or a salt or a composition containing a therapeutically effective amount of a compound of formula I, an enantiomer or a racemate or a salt thereof can be administered by methods well known in the art Thus, a compound of formula I, or a salt thereof can be administered either singly or with other pharmaceutical agents, for example, antihistamines, mediator release inhibitors, methyl xanthines, beta agonists or antiasthmatic steroids such as prednisone and prednisolone, orally, parenterally, rectally, or by inhalation, for example in the form of an aerosol, micropulverized powder or nebulized solution. For oral administration they can be administered in the form of tablets, capsules, for example, in admixture with talc, starch, milk sugar or other inert ingredients, that is, pharmaceutical^ acceptable carriers, or in the form of aqueous solutions, suspensions, elixirs or aqueous alcoholic solutions, for example, in admixture with sugar or other sweetening agents, flavoring agents, colorants, thickeners and other conventional pharmaceutical excipients. For parenteral administration, they can be administered as solutions or suspension, for example, as an aqueous or peanut oil solution or suspension using excipients and carriers conventional for this mode of administration. For administration as aerosols, they can be dissolved in a suitable pharmaceutical^ acceptable solvent, for example, ethyl alcohol or combinations of miscible solvents, and mixed with a pharmaceutical^ acceptable propellant. Such aerosol compositions are packaged for use in pressurized container fitted with an aerosol valve suitable for release of the pressurized composition. Preferably, the aerosol valve is a metered valve, that is one which on activation releases a predetermined effective dose of the aerosol composition.
Since compounds of formula I of the invention may possess an asymmetric carbon atom, they are ordinarily obtained as racemic mixtures. It is to be understood the enantiomers and diastereomers also form part of this invention. The resolution of such racemates into the optically active isomers can be carried out by known procedures. Some racemic mixtures can be precipitated as eutectics and can thereafter be separated. Chemical resolution is, however, preferred. By this method, diastereomers are formed from the racemic mixture of a compound of formula I, with an optically active resolving agent. The formed diastereomers are separated by selective crystallization or chromatography and converted to the corresponding optical isomer. Thus the invention covers the racemates of the compounds of formula I as well as their optically active isomers (enantiomers).
The examples which follow further illustrate the invention.
In the following examples, the "usual work-up" procedure involves three extractions with the specified solvent. The organic extracts were combined, washed with water and saturated brine, dried over anhydrous magnesium sulfate, filtered, and concentrated under water aspirator pressure. The residue was dried to constant weight at 45°C/high vacuum. All reactions except hydrogenations were carried out under an inert atmosphere of nitrogen or argon. wo 95/28386 pct/ep95/01262 Example 1 Preparation of 2-(6-Iodohexyl)-6-(4-methoxy-4-oxobutoxy)-benzenepropanoic acid methyl ester.
A mixture of 10.81 g (ca. 23.37 mmol) of crude 2-(4-methoxy-4-oxobutoxy)-6-[6-[(methylsulfonyl)oxy]hexyl]-benzenepropanoic acid methyl ester, 7.01 g (46.7 mmol) of anhydrous sodium iodide, and 44 mL of dry acetonitrile was stirred at room temperature for 17 hr and then refluxed for 3.5 hr. After being cooled, the mixture was diluted with 200 mL of ether and filtered with suction. The solids were washed thoroughly with ether. The filtrate and washes were combined and washed with 12% aqueous sodium bisulfite, and work-up was completed in the usual manner. There was obtained 11.14 g (97.3%) of 2-(6-iodohexyl)-6-(4-methoxy-4-oxobutoxy)-benzenepropanoic acid methyl ester as a yellow oil.
Example 2 Preparation of 2-[6-[(4,6-Diphenyl-2-pyridinyl)oxy]hexyl]-6-(4-methoxy-4-oxobutoxy)benzenepropanoic acid methyl ester.
A mixture of 12.86 g (26.24 mmol) of 2-(6-iodohexyl)-6-(4-methoxy-4-oxobutoxy)benzenepropanoic acid methyl ester, 6.18 g (25 mmol) of 4,6-diphenyl-2-pyridone, 3.45 g (12.51 mmol) of silver carbonate, and 250 mL of toluene was stirred and refluxed for 18 hr. After being cooled, the mixture was filtered with suction through a pad of Celite. The solid cake was washed well with toluene. The filtrate and washes were combined and concentrated in vacuo giving a yellow oil. This material was treated with 1 g (4.05 mmol) of the pyridone, 3.45 g (12.51 mmol) of fresh silver carbonate, and 250 mL of toluene. The mixture was stirred under reflux for an additional 2 hr and at room temperature for 16 hr. Work-up as before gave 17.96 g of an oily product. This material was chromatographed on silica gel, eluting with hexane-ethyl acetate mixtures. There was obtained 14.29 g (89.4%) of pure title dimethyl ester, as a viscous, amber oil.
Example 3 Preparation of 2-(3-Carboxypropoxy)-6-[6-[(4,6-diphenyl-2-pyridinyl)oxy]hexyl]benzenepropanoic acid.
A mixture of 2-[6-[(4,6-diphenyl-2-pyridinyl)oxy]hexyl]-6-(4-methoxy-4-oxobutoxy)benzenepropanoic acid methyl ester (preceding example) (14.29 g; 23.46 mmol), 4.48 g (70.4 mmol) of potassium hydroxide, and 250 mL of methanol was stirred and refluxed, for 4.5 hr. The resulting pale-yellow solution was concentrated in vacuo to remove most of the solvent and the residue was dissolved in water and acidified with i£L aqueous hydrochloric acid. The mixture was worked-up with dichloromethane ih the usual manner giving a viscous, yellow gum. Thin layer chromatographic and NMR spectral analysis of this product revealed that saponification was incomplete. Therefore, this material was redissolved in 250 mL of methanol and 7.5 g (117.86 mmol) of potassium hydroxide was added. The solution was stirred and refluxed for 21 hr before being concentrated in vacuo. The residual paste was taken up in 250 mL of water and the resulting milky solution was filtered with suction. The filtrate was acidified with 3N. aqueous hydrochloric acid and worked-up with ether in the usual manner. There was obtained 13.18 g of a pale-yellow solid which was recrystallized from acetonitrile giving 12.48 g (91.6%) of the pure title diacid, as a colorless solid, mp 77-79 °C.
Anal. Calcd for C36H39NO6: C, 74.33; H, 6.76; N, 2.41. Found: C, 74.14; H, 6.64; N, 2.40.
Example 4 Preparation of rac-(E)-3-[2-[(4-Hydroxy-4-methyl-2-pentynyl)-oxy]-6-[6-[(tetrahydro-2H-pyran-2-yl)oxy]-l-hexynyl]phenyl]-2-propenoic acid methyl ester.
A mixture of 1.08 g (6.11 mmol) of 5-bromo-2-methyl-3-pentyn-2-ol, 2.19 g (6.11 mmol) of rac-(E)-3-[2-hydroxy-6-[6-[(tetrahydro-2H-pyran-2-yl)oxy]-l-hexynyl]phenyl]-2-propenoic acid methyl ester, 3.38 g (24.45 mmol) of anhydrous, granular potassium carbonate in 50 mL of 2-butanone was stirred and heated at reflux for 5.33 hr. Another portion of 5-bromo-2-methyl-3-pentyn-2-ol (0.17 g; 0.94 mmol) and 10 mL of 2-butanone were added and the reaction was allowed to proceed for another 17.33 hr. After being cooled to room temperature, the mixture was filtered through some anhydrous magnesium sulfate and the solids were washed thoroughly with ethyl acetate. The filtrate and the washings were combined and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel, eluting with hexane-ethyl acetate (3:1) to afford 2.52 g (90.6%) of the title compound as a yellow oil.
Anal. Calcd for C27H34O6: C, 71.34; H, 7.54. Found: C, 71.31; H, 7.36.
Example 5 Preparation of rac-2-[(4-Hydroxy-4-methylpentyl)oxy]-6-[6-[(tetrahydro-2H-pyran-2-yl)oxy]hexyl]benzenepropanoic acid methyl ester.
To a solution of 2.4 g (5.28 mmol) of rac-(E)-3-[2-[(4-hydroxy-4-methyl-2-pentynyl)oxy]-6-[6-[(tetrahydro-2H-pyran-2-yl)oxy]-l-hexynyl]phenyl]-2-propenoic acid methyl ester in 100 mL of ethyl acetate was added 1.0 g of 10% Pd/C and the mixture was hydrogenated at atmospheric pressure and room temperature overnight. The mixture was filtered through a pad of celite, and the solids were washed thoroughly with ethyl acetate. After removal of the solvent, the crude product was purified by flash chromatography on silica gel, eluting with hexane-ethyl acetate (3:1), to afford 2.01 g (81.8%) of the title compound as a colorless oil.
Anal. Calcd for C27H44O6: C, 69.79; H, 9.55. Found: C, 69.98; H, 9.40.
Example 6 Preparation of 2-(6-Hydroxyhexyl)-6-[(4-hydroxy-4-methylpentyl)oxy]benzenepropanoic acid methyl ester.
To a solution of 2.0 g (4.3 mmol) of rac-2-[(4-hydroxy-4-methylpentyl)oxy]-6-[6-[(tetrahydro-2H-pyran-2-yl)oxy]hexyl]-benzenepropanoic acid methyl ester in 75 mL of methanol were added 10 mL of water and 2.0 g (15.86 mmol) of oxalic acid dihydrate and the resulting solution was stirred at room temperature for 17 hr. Most of the methanol was removed under reduced pressure and the residue was taken up in ethyl acetate. The ethyl acetate solution was then washed twice with water. After completion of the usual workup, the crude product was purified by flash chromatography on silica gel, eluting with hexane-ethyl acetate (2:1 then 1:1) to give 1.40 g (85.2%) of the title compound as a pale yellow oil.
Anal. Calcd for C22H36O5: C, 69.44; H, 9.54. Found: C, 69.22; H, 9.51.
Example 7 Preparation of 2-(6-Bromohexyl)-6-[(4-hydroxy-4-methyl-pentyl)oxy]benzenepropanoic acid methyl ester.
To a mixture of 1.36 g (3.56 mmol) of 2-(6-hydroxy-hexyl)-6-[(4-hydroxy-4-methylpentyl)oxy]benzenepropanoic acid methyl ester, 1.77 g (5.34 mmol) of carbon tetrabromide and 1.40 g (5.34 mmol) of triphenylphosphine was added 75 mL of ether and the resulting mixture was stirred at room temperature for 24 hr. Additional portions of carbon tetrabromide (1.77 g; 5.34 mmol) and triphenylphosphine (1.40 g; 5.34 mmol) were added and the reaction was allowed to proceed for another 17.25 hr. The mixture was filtered through anhydrous magnesium sulfate, and the solids were washed thoroughly with ether. After the usual workup, the crude product was purified by flash chromatography on silica gel, eluting with hexane-ethyl acetate (3:1), to give 1.04 g (65.5 %) of the title compound as a colorless oil.
Anal. Calcd for C22H35Br04: C, 59.59; H, 7.96; Br, 18.02. Found: C, 59.66; H, 8.14; Br, 17.77.
Example 8 Preparation of 2-[6-[(4,6-Diphenyl-2-pyridinyl)oxy]hexyl]-6-[(4-hydroxy-4-methylpentyl)oxy]benzenepropanoic acid methyl ester.
A mixture of 0.29 g (1.17 mmol) of 4,6-diphenyl-2-pyridone, 0.52 g (1.17 mmol) of 2-(6-bromohexyl)-6-[(4-hydroxy-4-methylpentyl)oxy]benzenepropanoic acid methyl ester, 0.33 g (1.19 mmol) of silver carbonate and 40 mL of toluene was stirred and refluxed, with protection from light by aluminum foil, for 46.2 hr. The mixture was cooled to room temperature, filtered through some anhydrous magnesium WO 95/28386 PCT/EP95/01262 sulfate, and the solids were washed with ethyl acetate. After concentrating the combined filtrate and washes, the crude product was purified by flash chromatography on silica gel, eluting with hexane-ethyl acetate (3:1), to afford 0.60 g (84.7%) 5 of the title compound as a light tan oil.
Anal. Calcd for C39H47NO5: C, 76.82; H, 7.77; N, 2.30. Found: C, 76.63; H, 7.71; N, 2.30.
Example 9 Preparation of 2-[6-[(4,6-Diphenyl-2-pyridinyl)oxy]hexyl]-6-[(4-hydroxy-4-methylpentyl)oxy]benzenepropanoic acid.
To a mixture of 0.60 g (0.99 mmol) of 2-[6-[(4,6-diphenyl-15 2-pyridinyl)oxy]hexyl]-6-[(4-hydroxy-4-methylpentyl)oxy]-benzene-propanoic acid methyl ester in 13 mL of THF and 13 mL of water was added 85.0 mg (2.03 mmol) of lithium hydroxide monohydrate and the resulting mixture was stirred at room temperature for 42.5 hr. The solution was acidified with 20 the addition of 25 mL of 3H. sulfuric acid solution, and the resulting mixture was worked-up with ethyl acetate in the usual manner. The crude product was recrystallized from hexane-ethyl acetate to give 0.51 g (86.1%) of the title compound as a white solid, mp 83-84.5 °C.
Anal. Calcd for C38H45NO5: C, 76.61; H, 7.61; N, 2.35.
Found: C, 76.60; H, 7.76; N, 2.24.
Example 10 Preparation of rac-(E)-3-[2-[4-(Methylsulfonyl)butoxy]-6-[6-[(tetrahydro-2H-pyran-2-yl)oxy]-l-hexynyl]phenyl]-2-propenoic acid methyl ester.
Starting with 1.16 g (3.23 mmol) of rac-(£)-3-[2-hydroxy-35 6-[6-[(tetrahydro-2H-pyran-2-yl)oxy]-l-hexynyl]phenyl]-2- propenoic acid methyl ester and 0.71 g (3.30 mmol) of 4-(methylsulfonyl)butyl bromide, the title compound (1.39 g; 87.4%) was obtained as a white solid, mp 42-43 °C, following the procedure of Example 4.
Anal. Calcd for C26H36O7S: C, 63.39; H, 7.37; S, 6.51. Found: C, 63.25; H, 7.20; S, 6.50.
Example rn Preparation of rac-2-[4-(Methylsulfonyl)butoxy]-6-[6-[(tetrahydro-2H-pyran-2-yl)oxy]hexyl]benzenepropanoic Acid Methyl Ester.
Starting with 1.33 g (2.71 mmol) of rac-QE_)-3-[2-[4-(methylsulfonyl)butoxy]-6-[6-[(tetrahydro-2H-pyran-2-yl)oxy]-l-hexynyl]phenyl]-2-propenoic acid methyl ester, hydrogenation following the procedure of Example 5 gave the title compound (1.23 g; 90.8%) as a colorless oil.
Anal. Calcd for C26H42O7S: C, 62.62; H, 8.49; S, 6.43. Found: C, 62.27; H, 8.75; S, 6.41.
Example \2 Preparation of 2-(6-Hydroxyhexyl)-6-[4-(methylsulfonyl)-butoxy]benzenepropanoic acid methyl ester.
Starting with 1.18 g (2.37 mmol) of rac-2-[4-(methyl-sulfonyl)butoxy]-6-[6-[(tetrahydro-2H-pyran-2-yl)oxy]hexyl]-benzenepropanoic acid methyl ester, hydrolysis following the procedure of Example 6 gave the title compound (0.79 g; 80.6%) as a colorless oil.
Anal. Calcd for C21H34O6S: C, 60.83; H, 8.27; S, 7.73. Found: C, 61.02; H, 8.16; S, 7.45.
Example 13 Preparation of 2-(6-Bromohexyl)-6-[4-(methylsulfonyl)butoxy]-benzenepropanoic acid methyl ester.
Starting with 0.72 g (1.73 mmol) of 2-(6-hydroxyhexyl)-6-[4-(methylsulfonyl)butoxy]benzenepropanoic acid methyl ester, the title compound (0.71 g; 86.1%) was obtained as a colorless oil, following the procedure of Example 7.
Anal. Calcd for C2lH33Br05S: C, 52.83; H, 6.97; Br, 16.74; S, 6.72. Found: C, 53.03; H, 6.90; Br, 16.49; S, 6.56.
Example 14 Preparation of 2-[6-[(4,6-Diphenyl-2-pyridinyl)oxy]hexyl]-6-[4-(methylsulfonyl)butoxy]benzenepropanoic acid methyl ester.
Starting with 0.34 g (1.39 mmol) of 4,6-diphenyl-2-pyridone and 0.66 g (1.39 mmol) of 2-(6-bromohexyl)-6-[4-(methylsulfonyl)butoxy]benzenepropanoic acid methyl ester, the title compound (0.86 g; 96.2%) was obtained as a colorless oil, following the procedure of Example 8.
Example 15 Preparation of 2-[6-[(4,6-Diphenyl-2-pyridinyl)oxy]hexyl]-6-[4-(methylsulfonyl)butoxy]benzenepropanoic acid.
Starting with 0.77 g (1.20 mmol) of 2-[6-[(4,6-diphenyl-2-pyridinyl)oxy]hexyl]-6-[4-(methylsulfonyl)butoxy]benzene-propanoic acid methyl ester, hydrolysis following the procedure of Example 9 gave the title compound (0.49 g; 64.5%) as a white solid, mp 72.5-74.5 °C (recrystallized from hexane-ethyl acetate).
Anal. Calcd for C37H43NO6S: C, 70.56; H, 6.88; N, 2.22; S, 5.09. Found: C, 70.26; H, 6.84; N, 2.05; S, 5.10.
Example 16 Preparation of rac-2-Hydroxy-6-[6-[(tetrahydro-2H-pyran-2-yl)oxy]hexyl]benzenepropanoic acid methyl ester.
Starting with 3.29 g (9.19 mmol) of rac-(E>3-[2-hydroxy-6-[6-[(tetrahydro-2H-pyran-2-yl)oxy]-l-hexynyl]phenyl]-2-propenoic acid methyl ester, hydrogenation following the procedure of Example 5 gave the title compound (3.07 g; 91.6%) as a colorless oil.
Anal. Calcd for C21H32O5: C, 69.20; H, 8.85. Found: C, 69.26; H, 8.87.
Example 17 Preparation of 2-Hydroxy-6-(6-hydroxyhexyl)benzene-propanoic acid methyl ester.
Starting with 3.02 g (8.29 mmol) of rac-2-hydroxy-6-[6-[(tetrahydro-2H-pyran-2-yl)oxy]hexyl]benzenepropanoic acid methyl ester, hydrolysis following the procedure of Example 6 gave the title compound (2.13 g; 91.7%) as a colorless oil.
Anal. Calcd for C16H24O4* C, 68.55; H, 8.63. Found: C, 68.19; H, 8.18.
Example 18 Preparation of 3-Hydroxy-2-(3-hydroxy-3-methylbutyl)-benzenehexanol.
To a stirred solution of 2.0 g (7.13 mmol) of 2-hydroxy-6-(6-hydroxyhexyl)benzenepropanoic acid methyl ester in 40 mL of THF was added 20 mL of methylmagnesium chloride solution in THF (3M: 60 mmol), at room temperature, and the resulting solution was then refluxed for 4.33 hr. After being cooled to room temperature, the reaction mixture was treated with 75 mL of 1£L aqueous sulfuric acid and the mixture was worked-up with ethyl acetate in the usual manner. The crude product was purified by flash chromatography on silica gel, eluting with hexane-ethyl acetate (1:1), to afford 1.81 g (90.6%) of the title compound as a white solid, mp 72-73.5 °C.
Anal. Calcd for C17H28O3: C, 72.82; H, 10.07. Found: C, 72.79; H, 10.30.
Example 19 Preparation of 4-[3-(6-Hydroxyhexyl)-2-(3-hydroxy-3-methylbutyl)phenoxy]butanoic acid ethyl ester.
A mixture of 0.68 g (2.41 mmol) of 3-hydroxy-2-(3-hydroxy-3-methylbutyl)benzenehexanol, 0.47 g (2.42 mmol) of ethyl 4-bromobutyrate and 1.33 g (9.66 mmol) of anhydrous, granular potassium carbonate in 25 mL of 2-butanone was stirred and refluxed for 21.5 hr. A second portion of ethyl 4-bromobutyrate (0.24 g; 1.25 mmol) in 5 mL of 2-butanone was added and the reaction mixture was stirred and refluxed for an additional 22 hr. After being cooled to room temperature, the mixture was filtered through some anhydrous magnesium sulfate, and the solids were washed thoroughly with ethyl acetate. The filtrate and the washings were combined and concentrated. A second run was carried out starting with 0.91 g (3.24 mmol) of 3-hydroxy-2-(3-hydroxy-3-methylbutyl)-benzenehexanol. The crude products from both runs were combined and purified by flash chromatography on silica gel, eluting with hexane-ethyl acetate (1:1), to afford 2.09 g (93.7%) of the title compound as a colorless oil.
Anal. Calcd for C23H38O5: C, 70.02; H, 9.71. Found: C, 69.99; H, 9.57.
Example 20 Preparation of 4-[3-(6-Bromohexyl)-2-(3-hydroxy-3-methylbutyl)phenoxy]butanoic acid ethyl ester.
Starting with 2.04 g (5.16 mmol) of 4-[3-(6-hydroxy-hexyl)-2-(3-hydroxy-3-methylbutyl)phenoxy]butanoic acid ethyl ester, the title compound (2.11 g; 89.4%) was obtained as a colorless oil, following the procedure of Example 7.
Anal. Calcd for C23H37BrC>4: C, 60.39; H, 8.15; Br, 17.47. Found: C, 60.36; H, 8.06; Br, 17.66.
Example 21 Preparation of 4-[3-[6-[(4,6-Diphenyl-2-pyridinyl)oxy]hexyl]-2-(3-hydroxy-3-methylbutyl)phenoxy]butanoic acid ethyl ester.
Starting with a mixture of 0.59 g (2.39 mmol) of 4,6-diphenyl-2-pyridone and 1.09 g (2.39 mmol) of 4-[3-(6-bromohexyl)-2-(3-hydroxy-3-methylbutyl)phenoxy]butanoic acid ethyl ester, the title compound (1.43 g; 95.8%) was obtained as a colorless oil, following the procedure of Example 8.
Anal. Calcd for C40H49NO5: C, 77.01; H, 7.92; N, 2.25. Found: C, 76.54; H, 7.77; N, 2.15.
Example 22 Preparation of 4-[3-[6-[(4,6-Diphenyl-2-pyridinyl)oxy]hexyl]-2-(3 -hy droxy-3 -methylbutyl)phenoxy ] butanoic acid.
Starting with 1.36 g (2.18 mmol) of 4-[3-[6-[(4,6-diphenyl-2-pyridinyl)oxy]hexyl]-2-(3-hydroxy-3-methylbutyl)- phenoxy]butanoic acid ethyl ester and following the procedure of Example 9, the title compound (1.08 g; 83.6%) was obtained as a white solid, mp 97.5-98.5 °C (recrystallized from hexane-ethyl acetate).
Anal. Calcd for C38H45NO5: C, 76.61; H, 7.61; N, 2.35. Found: C, 76.30; H, 7.88; N, 2.26.
Example 23 Preparation of 4-[6-[(4,6-Diphenyl-2-pyridinyl)oxy]hexyl]-3-(3-ethoxy-3-oxopropyl)benzenpentanoic acid ethyl ester.
Starting with a mixture of 0.24 g (0.97 mmol) of 4,6-diphenyl-2-pyridone and 0.46 g (0.97 mmol) of 4-(6-bromohexyl)-3-(3-ethoxy-3-oxopropyl)benzenepentanoic acid ethyl ester, the title compound (0.56 g; 90.3%) was obtained as a colorless oil, following the procedure of Example 8.
Anal. Calcd for C41H49NO5: C, 77.45; H, 7.77; N, 2.20. Found: C, 77.22; H, 7.52; N, 2.11.
Example 24 Preparation of 3-(2-Carboxyethyl)-4-[6-[(4,6-diphenyl-2-pyridinyl)oxy]hexyl]benzenepentanoic Acid.
Starting with 0.49 g (0.77 mmol) of 4-[6-[(4,6-diphenyl-2-pyridinyl)oxy]hexyl]-3-(3-ethoxy-3-oxopropyl)benzene-pentanoic acid ethyl ester and following the procedure of Example 9, the title compound (0.37 g; 82.9%) was obtained as a white solid, mp 104.5-106.5°C (recrystallized from hexane-ethyl acetate).
Example 25 Preparation of 2-[6-[(4,6-Diphenyl-2-pyridinyl)oxy]hexyl]-5-(4-methoxy-4-oxobutoxy)benzenepropanoic acid methyl ester.
A mixture of 0.68 g (2.75 mmol) of 4,6-diphenyl-2-pyridone, 1.145 g (2.50 mmol) of 2-[6-[(methylsulfonyl)oxy]-hexyl]-5-(4-methoxy-4-oxobutoxy)benzenepropanoic acid methyl ester, 0.76 g (5.5 mmol) of anhydrous potassium carbonate, 0.037 g (0.25 mmol) of sodium iodide, and 6.2 mL of N.N-dimethylformamide was stirred and heated at 85-90 °C. for 16 hr. The reaction mixture was cooled and filtered with suction. The solids were washed with ethyl acetate and then the filtrate and washes were combined and concentrated in vacuo. The oily residue was flash-chromatographed on silica gel, eluting with hexane-ether mixtures. There was obtained 0.56 g (37%) of the title diester as a pale-yellow oil.
Example 26 Preparation of 5-(3-Carboxypropoxy)-2-[6-[(4,6-diphenyl-2-pyridinyl)oxy]hexyl]benzenepropanoic acid.
A mixture of 0.56 g (0.92 mmol) of 2-[6-[(4,6-diphenyl-2-pyridinyl)oxy]hexyl]-5-(4-methoxy-4-oxobutoxy)benzene-propanoic acid methyl ester from the preceding example, 0.26 g (4.64 mmol) of potassium hydroxide, and 15 mL of methanol was stirred and refluxed for 20 hr. The resulting solution was cooled and concentrated in vacuo. The residue was dissolved in water and the aqueous, alkaline solution was extracted once with ether (the extract was discarded) before being acidified with 3£T HC1. The mixture was worked-up with dichloromethane in the usual manner giving a solid product. Recrystallization from acetonitrile gave the title diacid (0.4 g; 75%) as a colorless solid, mp 133-134 °C.
Anal. Calcd for C36H39NO6: C, 74.33; H, 6.76; N, 2.41. Found: C, 73.92; H, 6.60; N, 2.34.
EXAMPLE 27 Preparation of 2-[6-[[6-(4-Fluorophenyl)-4-phenyl-2-pyridinyl]-oxy]hexyl]-6-(4-methoxy-4-oxobutoxy) benzenepropanoic Acid Methyl Ester.
Using the procedure of Example 2, 4-phenyl-6-(4-fluoro-phenyl)-2-pyridone was alkylated with 2-(6-iodohexyl)-6-(4-methoxy-4-oxobutoxy)benzenepropanoic acid methyl ester giving the title diester in quantitative yield, as a pale-yellow oil.
EXAMPLE 28 Preparation of 2-(3-Carboxypropoxy)-6-[f6-(4-fluoro-phenyl)-4-phenyl-2-pyridinyl)oxy]hexyl]benzenepropanoic Acid.
Using the procedure of Example 3, 2-[6-[[6-(4-fluorophenyl)-4-phenyl-2-pyridinyl]oxy]hexyl]-6-(4-methoxy-4-oxobutoxy)benzene-propanoic acid methyl ester from the preceding Example was saponified giving the title diacid monohydrate, in 29% yield, as a colorless solid, mp 78.5-81.0 °C., recrystallized from acetonitrile.
Anal. Calcd for C36H38FN06-H20: C, 70.00; H, 6.53; N, 2.27. Found: C, 70.25; H, 6.27; N, 2.24.
P CT/EP95/01262 EXAMPLE 29 Preparation of 2-(4-Methoxy-4-oxobutoxy)-6-[6-[[4-phenyl-6-(2-thienyl)-2-pyridinyl]oxy]hexyl]benzene-propanoic Acid Methyl Ester.
Using the procedure of Example 2, 4-phenyl-6-(2-thienyl)-2-pyridone was alkylated with 2-(6-iodohexyl)-6-(4-methoxy-4-oxobutoxy)benzenepropanoic acid methyl ester giving the title diester in 94% yield, as a pale-yellow oil.
EXAMPLE 3Q Preparation of 2-(3-Carboxypropoxy)-6-[6-[[4-phenyl-6-(2-thienyl)-2-pyridinyl]oxy]hexyl]benzenepropanoic Acid.
Using the procedure of Example 3, 2-(4-methoxy-4-oxo-butoxy)-6-[6-[[4-phenyl-6-(2-thienyl)-2-pyridinyl]oxy]hexyl] benzenepropanoic acid methyl ester from the preceding Example was saponified giving the title diacid, in 33% yield, as a colorless solid, mp 119.0-120.5 °C., recrystallized from acetonitrile.
Anal. Calcd for C34H37NO6S: C, 69.48; H, 6.35; N, 2.38.
Found: C, 69.43; H, 6.47; N, 2.29.
EXAMPLE 31 Preparation of 2-(6-Hydroxyhexyl)-6-[[4-(methoxy-carbonyl)-phenyl]methoxy]benzenepropanoic Acid Methyl Ester.
A mixture of 1.15 g (3.16 mmol) of rac-2-hydroxy-6-[6-[(tetrahydro-2H-pyran-2-yl)oxy]hexyl]benzenepropanoic acid methyl ester from Example 16, 1.59 g (6.94 mmol) of 4-bromomethylbenzoic acid methyl ester and 2.62 g (18.93 mmol) of anhydrous, granular potassium carbonate in 30 mL of 2-butanone was heated at reflux in an oil bath for 20.5 hr. The mixture was cooled to room temperature and filtered through anhydrous magnesium sulfate. The filter cake was washed with ethyl acetate and then the filtrate and washes were combined and concentrate in vacuo. The residue was dissolved in 50 mL of methanol, concentrated sulfuric acid (1 mL) was added, and the resulting solution was stirred at room temperature for 21 hr.
Most of the methanol was removed in vacuo and the residue was taken up in 250 mL of ethyl acetate. The solution was washed with saturated sodium bicarbonate solution and work-up was completed in the usual manner. Flash chromatography of the residue on 200 g of silica gel (eluting with 2:1 hexane-'ithyl acetate) afforded 1.01 g (74.9%) of the title compound as a white solid, mp 60 °C.
Anal. Calcd for C25H32O6: C, 70.07; H, 7.53. Found: C, 69.97; H, 7.59.
EXAMPLE 32 Preparation of 2-(6-Bromohexyl)-6-[[4-(methoxy-carbonyl)-phenyl]methoxy] benzenepropanoic Acid Methyl Ester.
To a mixture of 0.50 g (1.17 mmol) of 2-(6-hydroxyhexyl)-6-[[4-(methoxycarbonyl)phenyl]methoxy]benzenepropanoic acid methyl ester, 1.17 g (3.51 mmoi) of carbon tetrabromide and 0.92 g (3.51 mmol) of triphenylphosphine was added 25 mL of ether and the resulting mixture was stirred at room temperature for 24.5 hr. The mixture was filtered through celite, and the filter cake was washed thoroughly with ether. The filtrate and washes were combined and concentrated in vacuo. Flash chromatography of the residue on 70 g of silica gel (eluting with 8:1 hexane-ethyl acetate) afforded 0.32 g (55.7%) of the title compound as a colorless oil.
Anal. Calcd for C25H3iBrOs: C, 61.10; H, 6.36; Br, 16.26. Found: C, 61.03; H, 6.52; Br, 16.36.
EXAMPLE 33 Preparation of 2-[6-[(4,6-Diphenyl-2-pyridinyl)oxy]hexyl]-6-[[4-(methoxycarbonyl)phenyl]methoxy]benzenepropanoic Acid Methyl Ester.
A mixture of 1.35 g of crude 2-(6-bromohexyl)-6-[[4-(methoxycarbonyl)phenyl]methoxy]benzenepropanoic acid methyl ester, 0.68 g (2.75 mmol) of 4,6-diphenyl-2-pyridone, and 0.76 g (2.75 mmol) of silver carbonate, in 50 mL of toluene was stirred and refluxed, protected from light, for 45.8 hr. The mixture was cooled to room temperature and filtered through anhydrous magnesium sulfate. The filter cake was washed thoroughly with ethyl acetate and then the filtrate and washes were combined and concentrated in vacuo. Flash chromatography of the residue on 300 g of silica gel (eluting with 7:1 hexane-ethyl acetate) afforded 1.06 g (71.3% for two steps) of the title compound as a pale yellow oil.
Anal. Calcd for C42H43NO6: C, 76.69; H, 6.59; N, 2.13. Found: C, 76.46; H, 6.56; N, 2.09.
EXAMPLE 34 Preparation of 2-[(4-Carboxyphenyl)methoxy]-6-[6-[(4,6-diphenyl-2-pyridinyl)oxy]hexyl]benzenepropanoic Acid.
To a mixture of 863.2 mg (1.31 mmol) of 2-[6-[(4,6-diphenyl-2-pyridinyl)oxy]hexyl]-6-[[4-(methoxycarbonyl)-phenyl]methoxy] benzenepropanoic acid methyl ester in 8 mL of tetrahydrofuran and 8 mL of water was added 187.8 mg (4.48 mmol) of lithium hydroxide monohydrate and the reaction mixture was stirred at room temperature for 113 hr. After the addition of 15 mL of 3££ aqueous sulfuric acid, the mixture was extracted twice with ethyl acetate. The organic solutions were combined and washed with 50 mL of 3£L aqueous sulfuric acid - SO - and work-up was completed in the usual manner. The crude product was recrystallized from hexane-ethyl acetate to give 688 mg (83.3%) of the title compound as an off-white solid, mp 100-103 °C.
Anal. Calcd for C4oH39N06: C, 76.29; H, 6.24; N, 2.22. Found: C, 75.98; H, 6.24; N, 2.16.
EXAMPLE 35 Preparation of 2-(6-Hydroxyhexyl)-6-[[2(methoxycarbonyl) phenyl]methoxy]benzenepropanoic Acid Methyl Ester.
Starting with 810 mg (2.22 mmol) of 2-hydroxy-6-[6-[(tetrahydro-2H-pyran-2-yl)oxy]hexyl] benzenepropanoic acid methyl ester and 1.12 g (4.89 mmol) of 2-bromomethylbenzoic acid methyl ester, the title compound (635 mg; 66.8%) was obtained as a tan solid, mp 43-44 °C., following the procedure of Example 31.
Anal. Calcd for C25H32O6: C, 70.07; H, 7.53. Found: C, 70.00; H, 7.62.
EXAMPLE 36 Preparation of 2-(6-Bromohexyl)-6-[[2-(methoxycarbonyl)-phenyl]methoxy]benzenepropanoic Acid Methyl Ester.
Starting with 470 mg (1.10 mmol) of 2-(6-hydroxyhexyl)-6-[[2-(methoxycarbonyl)phenyl]methoxy]benzenpropanoic acid methyl ester, the title compound (518 mg; 96.1%) was obtained as a colorless oil, following the procedure of Example 32.
Anal. Calcd for C25H3iBr05: C, 61.10; H, 6.36; Br, 16.26. Found: C, 61.09; H, 6.43; Br, 16.21.
EXAMPLE 37 Preparation of 2-[6-[(4,6-Diphenyl-2-pyridinyl)oxy]hexyl]-6-[[2-(methoxy carbonyl)phenyl] methoxy ]benzenepropanoic Acid Methyl Ester.
A mixture of 1.04 g of crude 2-(6-bromohexyl)-6-[[2-(methoxycarbonyl)phenyl]methoxy]benzenepropanoic acid methyl ester, 0.53 g (2.12 mmol) of 4,6-diphenyl-2-pyridone, and 0.59 g (2.12 mmol) of silver carbonate in 50 mL of toluene was stirred and refluxed, protected from light, for 67 hr. Workup as described in Example 33 gave a residue which was purified by flash chromatography on 300 g of silica gel (eluting with 6:1 hexane-ethyl acetate). This afforded 0.78 g (80.4% for 2 steps) of the tide compound as a yellow oil.
Anal. Calcd for C42H43N06: C, 76.69; H, 6.59; N, 2.13. Found: C, 76.53; H, 6.60; N, 2.17.
EXAMPLE 38 Preparation of 2-[(2-Carboxyphenyl)methoxy]-6-[6-[(4,6-diphenyl-2-pyridinyl)oxy]hexyl]benzenepropanoic Acid.
Starting with 732 mg (1.11 mmol) of 2-[6-[(4,6-diphenyl-2-pyridinyl)oxy]hexyl]-6-[[2-(methoxycarbonyl)phenyl]methoxy]-benzenepropanoic acid methyl ester and following the saponification procedure of Example 34, the title compound was obtained as a white solid, mp 134.5-137.5 °C. (recrystallized from hexane-ethyl acetate).
Anal. Calcd for C40H39NO6: C, 76.29; H, 6.24; N, 2.22. Found: C, 75.91; H, 6.09; N, 2.14.
EXAMPLE 39 Preparation of 2-(6-Hydroxyhexyl)-6-[[3(methoxy-carbonyl)-phenyl]methoxy]benzenpropanoic Acid Methyl Ester.
Starting with 1.35 g (3.69 mmol) of 2-hydroxy-6-[6-[(tetra-hydro-2H-pyran-2-yl)oxy]hexyl] benzenepropanoic acid methyl ester and 1.86 g (8.13 mmol) of 3-bromomethylbenzoic acid methyl ester, the title compound (1.11 g; 70.1%) was obtained as a colorless oil, following the procedure of Example 31.
Anal. Calcd for C25H32O6: C, 70.07; H, 7.53. Found: C, 69.91; H, 7.61.
EXAMPLE 40 Preparation of 2-(6-Bromohexyl)-6-[[3-(methoxycarbonyl)-phenyl]methoxy]benzenepropanoic Acid Methyl Ester.
Starting with 1.11 g (2.59 mmol) of 2-(6-hydroxyhexyl)-6-[[3-(methoxycarbonyl)phenyl]methoxy]benzenpropanoic acid methyl ester, the title compound (0.96 g; 75.7%) was obtained as a colorless oil, following the procedure of Example 32.
Anal. Calcd for C2sH3iBr05: C, 61.10; H, 6.36; Br, 16.26. Found: C, 61.08; H, 6.29; Br, 16.34.
EXAMPLE 41 Preparation of 2-[6-[(4,6-Diphenyl-2-pyridinyl)oxy]hexyl]-6-[[3-(methoxycarbonyl)phenyl]methoxy]benzenepropanoic Acid Methyl Ester.
A mixture of 919 mg (1.87 mmol) of 2-(6-bromohexyl)-6-[[3-(methoxycarbonyl)phenyl]methoxy]benzenepropanoic acid methyl ester, 462 mg (1.87 mmol) of 4,6-diphenyl-2-pyridone and 515 mg (1.87 mmol) of silver carbonate in 50 mL of toluene was stirred and refluxed for 44.7 hr. A second portion of 4,6-diphenyl-2-pyridone (100.2 mg; 0.41 mmol) was added and the reaction was continued for another 7 hr, and then cooled to room temperature while stirring for 3 d. Work-up as described in Example 33 gave a residue which was purified by flash chromatography on 300 g of silica gel (eluting with 6:1 hexane-ethyl acetate). This afforded 1.09 g (88.9%) of the title compound as a pale yellow oil.
Anal. Calcd for C42H43N06: C, 76.69; H, 6.59; N, 2.13. Found: C, 76.58; H, 6.47; N, 2.05.
EXAMPLE 42 Preparation of 2-[(3-Carboxyphenyl)methoxy]-6-[6-[(4,6-diphenyl-2-pyridinyl)oxy]hexyl] benzenepropanoic Acid.
Starting with 1.01 g (1.54 mmol) of 2-[6-[(4,6-diphenyl-2-pyridinyl)oxy]hexyl]-6-[[3-(methoxycarbonyl)phenyl]methoxy]-benzenepropanoic acid methyl ester and following the procedure of Example 34, the tide compound was obtained as an off-white solid, mp 157.5-159.5 °C. (recrystallized from hexane-ethyl acetate).
EXAMPLE 43 Preparation of 4-[(2-Oxo-2H-l-benzopyran-5-yl)oxy]- butanoic Acid Ethyl Ester.
A mixture of 8.78 g (54.15 mmol) of 5-hydroxycoumarin, 10.56 g of ethyl 4-bromobutyrate, 18.93 g (137 mmol) of anhydrous, granular potassium carbonate, and 50 mL of dry dimethyl sulfoxide was stirred at room temperature for 3 d. The resulting slurry was filtered with suction over a Celite pad and then the filter cake was washed with ethyl acetate. The filtrate and washes were combined and concentrated in vacuo. The residue was dissolved in ethyl acetate and the solution was washed 3 times with water. Work-up was completed in the usual manner giving an oil which was purified by flash chromatography on silica gel, eluting with hexane-ethyl acetate mixtures. There was obtained 9.90 g (66.2%) of the title ester as a pale-yellow oil.
EXAMPLE 44 Preparation of Qs)-4-[3-Hydroxy-2-(3-methoxy-3-oxo-l-propenyl)phenoxy]butanoic Acid Methyl Ester.
A solution of 9.90 g (35.87 mmol) of 4-[(2-oxo-2H-l-benzopyran-5-yl)oxy]butanoic acid ethyl ester from the preceding Example, 20 mL of 25% methanolic sodium methoxide, and 60 mL of methanol was stirred and refluxed for 32 lir and then kept at room temperature for 24 hr. The resulting yellow solution was concentrated in vacuo giving a solid residue which was treated with ethyl acetate and excess IK. aqueous hydrochloric acid. The mixture was worked-up with ethyl acetate and ether in the usual manner (the organic extracts were additionally washed with saturated, aqueous sodium bicarbonate solution) giving 9.42 g of a white solid. This material was dissolved in 50 mL of methanol and 0.934 g of p-toluenesulfonic acid monohydrate was added. The solution was stirred and refluxed for 24 hr and then cooled and concentrated in vacuo. The resiuue was worked-up with ethyl acetate in the usual manner (the organic extracts were additionally washed with saturated, aqueous sodium bicarbonate solution) giving 11.07 g of a beige solid. This material was purified by flash chromatography on 1500 g of silica gel, eluting with hexane-ethyl acetate mixtures. There was obtained 2.60 g (24.6%) of the pure title diester as a colorless solid.
EXAMPLE 45 Preparation of Q£)-4-[3-[(5-Bromopentyl)oxy)]-2-(3-methoxy-3-oxo-l-propenyl)phenoxy]butanoic Acid Methyl Ester.
A mixture of 2.60 g (8.84 mmol) of (E>4-[3-hydroxy-2-(3-methoxy-3-oxo-l-propenyl)phenoxy]butanoic acid methyl ester from the preceding Example, 9.73 mL (16.27 g; 70.75 mmol) of 1,5-dibromopentane, 3.86 g (27.99 mmol) of anhydrous, granular potassium carbonate, and 150 mL of acetonitrile was stirred at room temperature, for 48 hr. The resulting slurry was diluted with ether and filtered with suction over a pad of Celite. The filter cake was washed with ether and then the filtrate and washes were combined and concentrated in vacuo. The oily residue was flash chromatographed on 750 g of silica gel, eluting with hexane-ethyl acetate mixtures. There was obtained 3.20 g (81.6%) of the title bromide as a pale-yellow oil.
EXAMPLE 46 Preparation of QE)-4-[3-[[5-[(4,6-Diphenyl-2-pyridinyl)oxy] pentyl]oxy)]-2-(3-methoxy-3-oxo-l-propenyl)phenoxy]-butanoic Acid Methyl Ester.
Alkylation of 4,6-diphenyl-2-pyridone (1.23 g; 5 mmol) with (£)-4-[3-[(5-bromopentyl)oxy)]-2-(3-methoxy-3-oxo-l-propenyl)- phenoxy]butanoic acid methyl ester (2.22 g; 5 mmol) from the preceding Example, was carried out using the procedure of Example 2. There was obtained 2.19 g (72.0%) of the title compound as an oil.
EXAMPLE 47 Preparation of 2-[[5-[(4,6-Diphenyl-2-pyridinyl)oxy]- pentyl]-oxy]-6-(4-methoxy-4-oxobutoxy)benzenepropanoic Acid Methyl Ester.
A mixture of 2.19 g (3.59 mmol) of (E)-4-[3-[[5-[(4,6-diphenyl-2-pyridinyl)oxy]pentyl]oxy)]-2-(3-methoxy-3-oxo-l-propenyl)- phenoxy]butanoic acid methyl ester from the preceding Example, 0.219 g of 10% palladium on carbon, 25 mL of methanol, and 25 mL of ethyl acetate was stirred in an atmosphere of hydrogen, at room temperature, until gas uptake ceased. The mixture was filtered with suction over a pad of Celite and then the filter cake was washed with ethyl acetate. The filtrate and washes were combined and concentrated in vacuo. There was obtained 1.86 g (84.6%) of the title diester as a pale-yellow oil.
EXAMPLE 43 Preparation of 2-(3-Carboxypropoxy)-6-[[5-[(4,6-diphenyl-2-pyridinyl)oxy]pentyl]oxy]benzenepropanoic Acid.
Using the procedure of Example 3, 2-[[5-[(4,6-diphenyl-2-pyridinyl)oxy]pentyl]oxy]-6-(4-methoxy-4-oxobutoxy)benzene-propanoic acid methyl ester from the preceding Example was saponified giving the title diacid, in 46.9% yield, as a colorless solid, mp 130-131 °C., recrystallized from acetonitrile.
Anal. Calcd for C35H37NO7: C, 72.02; H, 6.39; N, 2.40. Found: C, 71.86; H, 6.35; N, 2.39.
EXAMPLE 49 Preparation of rac-(Ii)-3-[3-[2-(3-Methoxy-3-oxo-l-propenyl)-3-[6-[(tetrahydro-2H-pyran-2-yl)oxy]-l-hexynyl]phenoxy]propyl]-benzoic Acid Ethyl Ester.
A mixture of 1.45 g (4.04 mmol) of rac-(£)-3-[2-hydroxy-6-[6-[(tetrahydro-2H-pyran-2-yl)oxy]-l-hexynyl]phenyl]-2-propenoic acid methyl ester, 0.841 g (4.04 mmol) of 3-(3-hydroxypropyl)- benzoic acid ethyl ester, 3.15 g (12.0 mmol) of triphenylphosphine, 1.91 mL (12 mmol) of diethyl azodicar-boxylate, and 100 mL of dry tetrahydrofuran was stirred at room temperature for 3 d. Additional triphenylphosphine (3.15 g) and diethyl azodicarboxylate (1.91 mL) were added and stirring was continued for 24 hr. The reaction mixture was concentrated in vacuo and then the oily residue was flash chromatographed on 500 g of silica gel. Elution with hexane-ethyl acetate mixtures afforded 1.70 g (76.6%) of the title compound as a slightly pink oil.
EXAMPLE 50 Preparation of rac-2-[3-[3-(Ethoxycarbonyl)phenyl]- propoxy]-6-[6-[(tetrahydro-2H-pyran-2-yl)oxy]- hexyl] benzenepropanoic Acid Methyl Ester.
A mixture of 1.70 g (3.10 mmol) of rac-(E)-3-[3-[2-(3-methoxy-3-oxo-l-propenyl)-3-[6-[(tetrahydro-2H-pyran-2-yl)oxy]-l-hexynyl]phenoxy]propyl]benzoic acid ethyl ester from the preceding Example, 0.5 g of 10% palladium on carbon, and 170 mL of methanol was stirred in an atmosphere of hydrogen, at room temperature, until gas uptake ceased. The catalyst was removed by suction filtration over Celite and then the filtrate was concentrated in vacuo. There was obtained 1.53 g (89%) of the title compound as an oil.
EXAMPLE 51 Preparation of 2-[3-[3-(Methoxycarbonyl)phenyl]propoxy]-6-(6-hydroxyhexyl)benzenepropanoic Acid Methyl Ester.
A solution of 1.53 g (2.76 mmol) of rac-2-[3-[3-(ethoxy-carbonyl)phenyl]propoxy]-6-[6-[(tetrahydro-2H-pyran-2-yl)-oxy]hexyl]benzenepropanoic acid methyl ester from the preceding Example, 0.1 g of p-toluenesulfonic acid monohydrate, and 50 mL of methanol was stirred and refluxed for 20 hr before being cooled and concentrated in vacuo. The residue was worked-up with ether in the usual manner giving an oily residue, JH NMR analysis of which revealed complete removal of the tetrahydropyranyl protecting group but the presence of a mixture of methyl and ethyl esters. This material was retreated with methanol-p-toluenesulfonic acid monohydrate (24 hr reflux; 48 hr room temperature) affording 1.30 g (100%) of a yellow oil which was now mainly the desired, title dimethyl ester.
EXAMPLE 52 Preparation of 2-[3-[3-(Methoxycarbonyl)phenyl]propoxy]-6-[6-[(methylsulfonyl)oxy]hexyl]benzenepropanoic Acid Methyl Ester.
To a stirred solution of 1.30 g (ca. 2.76 mmol) of 2-[3-[3-(methoxycarbonyl)phenyl]propoxy]-6-(6-hydroxyhexyl)benzene-propanoic acid methyl ester from the preceding Example, 2.9 mL of triethylamine, and 20 mL of ethyl acetate was added 0.9 mL (11.63 mmol) of methanesulfonyl chloride, with ice-bath cooling. The resulting slurry was stirred at 0-5 °C. for 3.5 hr and then refrigerated for 24 hr. The reaction mixture was treated with 1M. hydrochloric acid and ice, and then worked-up with ether in the usual manner. This afforded 1.59 g (100%) of the title mesylate as a pale-yellow oil.
EXAMPLE 53 Preparation of 2-(6-Iodohexyl)-6-[3-[3-(methoxycarbonyl) phenyl]propoxy]benzenepropanoic Acid Methyl Ester.
Using the procedure of Example 1, 2-[3-[3-(methoxy-carbonyl)phenyl]propoxy]-6-[6-[(methylsulfonyl)oxy]hexyl]-benzenepropanoic acid methyl ester from the preceding Example was converted into the title iodide, an oil, in quantitative yield.
EXAMPLE 54 Preparation of 2-[6-[(4,6-Diphenyl-2-pyridinyl)oxy]hexyl]-6-[3-[3-(methoxycarbonyl)phenyl]propoxy]benzene-propanoic Acid Methyl Ester.
Using the procedure of Example 2, 0.828 g (3.35 mmol) of 4,6-diphenyl-2-pyridone was alkylated with 2-(6-iodohexyl)-6-[3-[3-(methoxycarbonyl)phenyl]propoxy]benzenepropanoic acid methyl ester from the preceding Example. There was obtained 0.96 g (50.8%) of the title diester as a pale-yellow oil.
EXAMPLE 55 Preparation of 2-[3-(3-Carboxyphenyl)propoxy]-6-[6-[(4,6-diphenyl-2-pyridinyl)oxy]hexyl]benzenepropanoic Acid.
Using the procedure of Example 3, 2-[6-[(4,6-diphenyl-2-pyridinyl)oxy]hexyl]-6-[3- i." -(methoxycarbonyl)phenyl] propoxy]benzenepropanoic acid methyl ester (0.96 g) from the preceding Example was saponified. There was obtained 0.58 g (63%) of the title diacid as a colorless solid, mp 102-105 °C., recrystallized from acetonitrile.
Anal. Calcd for C42H43N06: C, 76.69; H, 6.59; N, 2.13. Found: C, 76.39; H, 6.63; N, 2.12.
EXAMPLE 56 Preparation of rac-(E>2-[3-[2-(3-Methoxy-3-oxo-l-propenyl)-3-[6-[(tetrahydro-2H-pyran-2-yl)oxy]-l-hexynyl]phenoxy]propyl]-benzoic Acid Methyl Ester.
Using the procedure of Example 49, 1.45 g (4.04 mmol) of rac-(E3-3-[2-hydroxy-6-[6-[(tetrahydro-2H-pyran-2-yl)oxy]-l-hexyny!]phenyl]-2-propenoic acid methyl ester and 0.784 g (4.04 mmol) of 2-(3-hydroxypropyl)benzoic acid methyl ester were converted into the title diester, a colorless oil, in quantitative yield.
EXAMPLE 57 Preparation of rac-2-[3-[2-(Methoxycarbonyl)phenyl]- propoxy]-6-[6-[(tetrahydro-2H-pyran-2-yl)oxy]hexyl]- benzenepropanoic Acid Methyl Ester.
Using the procedure of Example 50, rac-(E)-2-[3-[2-(3-methoxy-3-oxo-l-propenyl)-3-[6-[(tetrahydro-2H-pyran-2-yl)oxy]-l-hexynyl]phenoxy]propyl]benzoic acid methyl ester from the preceding Example (2.2 g) was catalytically hydrogenated giving the title compound, a colorless oil, in 97% yield (2.11 g).
EXAMPLE 58 Preparation of 2-[3-[2-(Methoxycarbonyl)phenyl]propoxy]-6-(6-hydroxyhexyl)benzenepropanoic Acid Methyl Ester.
Using the procedure of Example 51 with the modification that only one methanol-p-toluenesulfonic acid treatment was employed, rac-2-[3-[2-(methoxycarbonyl)phenyl]propoxy]-6-[6-[(tetrahy dro-2H-pyran-2-yl)oxy ] hexy 1] benzenepropanoic acid methyl ester (2.11 g) from the preceding Example, was converted into the title compound, a colorless oil, in 95% yield (1.69 g).
EXAMPLE 59 Preparation of 2-[3-[2-(Methoxycarbonyl)phenyl]propoxy]-6-[6-[(methylsulfonyl)oxy]hexyl]benzenepropanoic Acid Methyl Ester.
Using the procedure of Example 52, 2-[3-[2-(methoxy-carbony l)phenyl]propoxy ] -6-(6-hydroxyhexyl) benzenepropanoic acid methyl ester from the preceding Example (1.69 g) was converted into the title mesylate, a yellow oil, in quantitative yield.
EXAMPLE ft? Preparation of 2-(6-Iodohexyl)-6-[3-[2-(methoxycarbonyl)-phenyl]propoxy]benzenepropanoic Acid Methyl Ester.
Using the procedure of Example 1, 2-[3-[2-(methoxy-carbony 1) pheny l]propoxy ]-6-[6-[(methylsulfonyl)oxy]hexyl] -benzenepropanoic acid methyl ester, from the preceding Example, was converted into the title iodide, a pale-yellow oil, in quantitative yield.
EXAMPLE 61 Preparation of 2-[6-[(4,6-Diphenyl-2-pyridinyl)oxy]hexyl]-6-[3-[2-(methoxycarbonyl)phenyl]propoxy]benzene-propanoic Acid Methyl Ester.
Using the procedure of Example 2, 0.998 g (4.04 mmol) of 4,6-diphenyl-2-pyridone was alkylated with 2-(6-iodohexyl)-6-[3-[2-(methoxycarbonyl)phenyl]propoxy]benzenepropanoic acid methyl ester from the preceding Example. There was obtained 2.02 g (80%) of the title diester as a pale-yellow oil.
EXAMPLE 62 Preparation of 2-[3-(2-Carboxyphenyl)propoxy]-6-[6-[(4,6-diphenyl-2-pyridinyl)oxy]hexyllbenzenepropanoic Acid.
Using the procedure of Example 3, 2-[6-[(4,6-diphenyl-2-pyridinyl)oxy]hexyl]-6-[3-[2-(methoxycarbonyl)phenyl]propoxy]-benzenepropanoic acid methyl ester (2.02 g) from the preceding Example was saponified. There was obtained 1.09 g (56%) of the title diacid as a colorless solid, mp 126-128 °C., recrystallized from acetonitrile.
Anal. Calcd for C42H43NO6: C, 76.69; H, 6.59; N, 2.13. Found: C, 76.30; H, 6.75; N, 2.07.
PC77EP95/01262 EXAMPLE 63 TABLET FORMULATION (Wet Granulation) Ingredients mg/taW?t 1. Compound A.* .0 .0 100.0 250.0 2. Lactose Anhydrous 108.4 88.4 89.0 222.5 3. Povidone K30 6.0 6.0 .0 .0 4. Magnesium Stearate 0.6 0.6 1.0 2.5 TOTAL 120.0 120.0 200.0 500.0 * Compound A is 2-(3-Carboxypropoxy)-6-[6-[[4,6-diphenyl-2-pyridinyl)oxy]hexyl]benzenepropanoic acid.
Manufacturing Procedure: 1) Mix Items 1 and 2 in a suitable mixer for 15 minutes. 2) Granulate the powder mix from Step 1 with 15% PVP K30 solution. 3) Dry the granulation from Step 2 at 50°C. 4) Pass the granulation from Step 3 through a suitable milling equipment.
) Add the Item 4 to the milled granulation from Step 4 and mix for 3 minutes. 6) Compress the granulation from Step 5 on a suitable press.

Claims (18)

WO 95/28386 - 64 -EXAMPLE 64 PCT/EF95/01262 CAPSULE FORMULATION Ingredients mg/capsuls 1. Compound A 5.0 25 100 2. Lactose Hydrous 159 124 143 3. Corn Starch 25 40 40 4. Talc 10.0 10.0 15 5. Magnesium Stearate 1.0 1.0 2 TOTAL 200.0 200.0 300.0 Manufacturing Procedure: 1) Mix Items 1, 2 and 3 in a suitable mixer for 30 minutes. 2) Add Items 4 and 5 and mix for 3 minutes. 3) Fill into suitable capsule. WO 95/28386 PCT/EP95/01262 - 65 - Claims 284069
1. A compound of the formula N'^CXCH^rt-tOL (XMCRWjnY z wherein X is O or C=0; Y is CN, S(0)uR8, NR5S02R8, OR9 R*0 0r -C6H4R10; Z is -(0)y-(CR5R6)s-RlO, -(0)y-(CR5R6)v.0R9 or RlO; R1, R3 are, independently, aryl, substituted aryl, heteroaryl, lower alkyl or aralkyl;;R2 is hydrogen, lower alkyl, halogen or lower alkoxy; R4 is hydrogen or lower alkyl;;r5, r6 are, independently, each occurrence, hydrogen or lower alkyl;;R? is hydroxy, lower alkoxy or NR5R6;;R8 is lower alkyl, aryl, substituted aryl or aralkyl;;R9 is hydrogen, lower alkyl, aryl, substituted aryl,;aralkyl, lower alkanoyl or aroyl;;RlO is COR?, CONHSO2R8 or lH-tetrazol-5-yl;;m is an integer from 3 to 8;;n and s are, independently, an integer from 1 to 12; t is an integer from 0 to 1;;u is an integer from 0 to 2;;v is an integer from 2 to 12;;y is an integer from 0 to 1; and z is an integer from 0 to 1;;with the proviso that either Y is R*0 or -C6H4R10 or Z is -(0)y-(CR5r6)s-r10 or rIO and the further proviso that when n=l, Y is RiO or -C6H4R10, WO 95/28386 PCT/EP95/01262 - 66 - ^ 28 4 0 69 an optical isomer when and R6 are not both hydrogen or the same lower alkyl and, when R? is hydroxy, a pharmaceutically acceptable salt thereof with a base.
2. A compound according to claim 1,wherein Rl and R3 are aryl and R2 and R4 are hydrogen.
3. A compound according to claim 1 or 2, wherein Y is R10 or -C6H4R10.
4. A compound according to any one of claims 1 to 3, wherein Z is -(0)y-(CR5R6)s.Rl() or RlO.
5. A compound according to claim 1 or claim 2, wherein Y is S(0)uR8, OR^ or RlO, and Z is-(0)y-(CRSR6)s-RlO or -(0)y-(CR5R6)v.OR9
6. A compound according to claim 1 or claim 2, wherein Y is RlO, Z is -(0)y-(CR5R6)v_OR9 0r -(0)y-(CR5R6)s-RlO, r7 is hydroxy, R^ is hydrogen, and RlO is -COR?.
7. A compound according to claim 6, wherein X is O, z is zero, t is 1, n is 3-5, y is zero and s or v is 2-6.
8. A compound according to claim 1 or claim 2, wherein Y is S(0)uR8 or OR9, Z is -(0)y-(CR5R6)s-RlOt r7 is hydroxy, R8 is lower alkyl, R^ is hydrogen and RlO is -COR?.
9. A compound according to claim 8, wherein X is O, z is zero, t is 1, n is 3-5, y is zero and s is 2-6.
10. A compound according to claim 1, wherein the compound of formula I is selected from the group consisting of 2-(3-carboxypropoxy)-6-[6-[(4,6-diphenyl-2-pyridinyl)oxy]-hexyl]-benzenepropanoic acid; 2-[6-[(4,6-diphenyl-2-pyridinyl)- N.2. PATCNJ Q»~F?CE 10 SEP 1997 WO 95/283S6 PCT/EP9S/01262 - 67 - 28 4 0 6 9 oxy]hexylj-6-[(4-hydroxy-4-methylpentyl)-oxy] benzenepropanoic acid; 2-[6-[(4,6-diphenyl-2-pyridinyl)oxy]hexyl]-6-[4-(methylsulfonyl)butoxy]-benzenepropanoic acid; 4-[3-[6-[(4,6-diphenyl-2-pyridiny l)pxy]ho:yl]-2-(3-hydroxy-3-methyl-butyl)phenoxy]butanoic acid; 3-(2-carboxyethyl)-4-[6-[(4,6-diphenyl-2-pyridinyl)oxy]hexyl]-b<iuzenepentanoic acid; and 5-(3-carboxypropoxy)-2-[6-[(4,6-diphenyl-2-pyridinyl)oxy]hexyl]-benzenepropanoic acid.
11. A compound according to claim 1, wherein the compound of formula I is selected from the group consisting of 2-[3-(2-carboxyphenyl)propoxy]-6-[6-[(4,6-diphenyl-2-pyridinyl)oxy]hexyl]benzenepropanoic acid; 2-[3-(3-carboxy-phenyl)propoxy]-6-[6-[(4,6-diphenyl-2-pyridinyl)oxy]hexyl]-benzenepropanoic acid; 2-(3-carboxypropoxy)-6-[5-[(4,6-diphenyl-2-pyridinyl)oxy]pentyloxy]benzenepropanoic acid; 2-(3-carboxypropoxy)-6-[6-[(4-phenyl-6-(4-fluorophenyl)-2-pyridinyl)oxy]hexyl]benzenepropanoic acid; 2-(3-carboxy-propoxy)-6-[6-[(4-phenyl-6-(2-thienyl)-2-pyridinyl)oxy]-hexyl]benzenepropanoic acid; 2-[(4-carboxyphenyl)methoxy]-6-[6-[(4,6-diphenyl-2-pyridinyl)oxy]- hexyl] benzenepropanoic acid; 2-[(2-carboxyphenyl)methoxy]-6-[6-[(4,6-diphenyl-2-pyridinyl)oxy]hexyl]benzenepropanoic acid; and 2-[(3-carboxy-phenyl)methoxy]-6-[6-[(4,6-diphenyl-2-pyridinyl)oxy]-hexyl]benzenepropanoic acid.
12. A pharmaceutical composition especially for the treatment or prevention of inflammatory diseases such as psoriasis, rhinitis, chronic obstructive pulmonary disese, inflammatory bowel disease, asthma, acute respiratory distress syndrome, cystic fibrosis, allergy, arthritis such as rheumatoid arthritis, dermatitis such as contact dermatitis, NSAID-induced gastropathy, gout, ischemia/perfusion injury and trauma-induced inflammation which contains an effective amount of a compound in accordance with any one of claims 1-11 or a f N.Z. PATENT OFFinF 1n Sep 1997 ! f J wo 95/28386 pct/ep95/01262 • "68" 28 4 0 69 pharmaceutically acceptable salt thereof with a base, and an inert carrier.
13. A process for the manufacture of compounds 5 according to any one of claims 1-11, which process comprises a) reacting a compound of the general formula 10 20 1-1 with a compound of the general formula CO ucHgw^r^A (xmcrSr6),^ 1-2 15 wherein L is a leaving group, R1, R2, R3, R4, R5, R6, X, m, n, z and t are as defined in claim 1 and Y' and Z are Y and Z as defined in claim 1 with the proviso that in any COR7 R7 is lower alkoxy, or b) saponifying a compound of the general formula I, wherein Y and/or Z contain(s) a -COR7 group and R7 is lower alkyl to mono- or di-acid derivatives, or 25 c) reacting a compound of the general formula I, wherein the group(s) Y and/or Z contain(s) the group -COOH, with an amine of the formula WO 95/28386 - 69 - PCT/EP95/01262 28 4 0 69 HNR5R13 wherein R5 is as defined in claim 1 and R13 is hydrogen, lower alkyl or a group -SO2R8 and R8 is as defined in claim 1, to the corresponding mono- or disubstituted amides or sulfonamides, or d) reacting a compound of the general formula I, wherein Y is -CN with a metal azide to a compound of the formula I, wherein Y is lH-tetrazol-5-yl, and e) if desired, converting a compound of the general formula I into a pharmaceutic ally acceptable salt.
14. Compounds in accordance with any one of claims 1-11 whenever prepared according to the process as claimed in claim 13 or by an obvious chemical equivalent thereof.
15. Compounds according to any one of claims 1-11 for use as therapeutically active substances especially for the treatment or prevention of inflammatory diseases such as psoriasis, rhinitis, chronic obstructive pulmonary disease, inflammatory bowel disease, asthma, acute respiratory distress syndrome, cystic fibrosis, allergy, arthritis such as rheumatoid arthritis, dermatitis such as contact dermatitis, NSAID-induced gastropathy, gout, ischemia/perfusion injury and trauma-induced inflammation.
16. The use of compounds according to any one of claims 1-11 for the manufacture of active pharmaceutical preparations, especially for the control or prevention of inflammatory diseases such as psoriasis, rhinitis, chronic obstructive pulmonary disease, inflammatory bowel disease, asthma, acute respiratory distress syndrome, cystic fibrosis, allergy, arthritis such as rheumatoid arthritis, dermatitis such as contact dermatitis, NSAID-induced gastropathy, gout, ischemia/perfusion injury and trauma-induced inflammation. 1 ^ SFP 1997 WO 95/28386 PCT/EP95/01262 - 70 - 28 4 0 6 9
17. A process for the manufacture of compounds according to any one of claims 1-11 substantially as hereinbefore described with particular reference to the foregoing Examples 1 to 62.
18. A pharmaceutical composition according to claim 12, substantially as hereinbefore described with particular reference to Examples 63 and 64. By the authorised agents A. J. PARK & SON
NZ284069A 1994-04-13 1995-04-06 Benzene alkanoic acid substituted pyridine derivatives; medicaments NZ284069A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22824694A 1994-04-13 1994-04-13
US39509295A 1995-03-06 1995-03-06
PCT/EP1995/001262 WO1995028386A1 (en) 1994-04-13 1995-04-06 Substituted pyridine leukotriene b4 antagonists

Publications (1)

Publication Number Publication Date
NZ284069A true NZ284069A (en) 1997-10-24

Family

ID=26922175

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ284069A NZ284069A (en) 1994-04-13 1995-04-06 Benzene alkanoic acid substituted pyridine derivatives; medicaments

Country Status (8)

Country Link
EP (1) EP0755381A1 (en)
JP (1) JP2866202B2 (en)
CN (1) CN1145619A (en)
AU (1) AU690258B2 (en)
BR (1) BR9507459A (en)
CA (1) CA2186252A1 (en)
NZ (1) NZ284069A (en)
WO (1) WO1995028386A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093253B2 (en) * 2008-03-06 2012-01-10 Hoffmann-La Roche Inc. Leukotriene B4 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05507475A (en) * 1990-06-07 1993-10-28 スミスクライン・ビーチャム・コーポレイション Benzoic acid derivatives for the treatment of leukotriene-related diseases
FR2665159B1 (en) * 1990-07-24 1992-11-13 Rhone Poulenc Sante NEW PYRIDINE AND QUINOLEIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.

Also Published As

Publication number Publication date
JPH09505605A (en) 1997-06-03
AU690258B2 (en) 1998-04-23
EP0755381A1 (en) 1997-01-29
WO1995028386A1 (en) 1995-10-26
CN1145619A (en) 1997-03-19
AU2256995A (en) 1995-11-10
JP2866202B2 (en) 1999-03-08
BR9507459A (en) 1997-11-11
CA2186252A1 (en) 1995-10-26

Similar Documents

Publication Publication Date Title
US5130318A (en) Angiotensin ii antagonizers which are condensed pyridine derivatives
AP161A (en) Novel Quinoline derivatives.
EP0420511B1 (en) Heterocyclic derivatives
US4507498A (en) Phenoxycarboxylic acids
CA1275102A (en) Intermediates for diphenyl and phenyl pyridyl anti- histamines
US5273999A (en) Carboxylic acid leukotriene B4 antagonists
EP0101330B1 (en) 2-quinolone derivatives
JPH0390063A (en) Disubstituted(quinoline-2-yl-methoxy) phenylacetic acid derivative
US4966907A (en) 6-substituted 5-hydroxy-2,3-dihydrobenzofurans as inhibitors of leukotriene biosynthesis
JP2520161B2 (en) Di-t-butylphenol substituted with an alkoxy group, a benzyloxy group or a benzylthio group
NZ284069A (en) Benzene alkanoic acid substituted pyridine derivatives; medicaments
US5219863A (en) Angiotensin ii antagonizing compounds containing a 1,5-naphthyridine or a quinoline moiety
CS226034B2 (en) Method of preparing pyridine derivatives
EP0905133A1 (en) Tetrazole derivatives as LTD4 and H1 antagonists
US5371227A (en) Quinoline derivatives, process for their preparation, and their therapeutic applications
JPH08508515A (en) Bicyclic Leucotriene Carboxylate B ▲ Lower 4 ▼ Antagonist
US4921867A (en) Pyridine compounds useful for therapy or prophylaxis of a disease associated with airway obstruction
US5633258A (en) Pyridine compounds for treating leukotriene-related diseases
JPS6353984B2 (en)
JPH0717588B2 (en) Substituted di-t-butylphenols
US5198439A (en) Angiotension II antagonizing pyridine derivatives
AU686820B2 (en) Quinoline derivatives as leukotriene antagonists
US4539419A (en) Naphthalenyloxy substituted carboxylic acids
WO1993022285A1 (en) Leukotriene antagonists
EP0219350A2 (en) Ethanolamine compounds